CN104206955A - 降血脂黑枸杞片 - Google Patents
降血脂黑枸杞片 Download PDFInfo
- Publication number
- CN104206955A CN104206955A CN201410415853.1A CN201410415853A CN104206955A CN 104206955 A CN104206955 A CN 104206955A CN 201410415853 A CN201410415853 A CN 201410415853A CN 104206955 A CN104206955 A CN 104206955A
- Authority
- CN
- China
- Prior art keywords
- blood
- effect
- kilograms
- extract
- liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 107
- 239000008280 blood Substances 0.000 title claims abstract description 107
- 230000001603 reducing effect Effects 0.000 title claims abstract description 58
- 241000169546 Lycium ruthenicum Species 0.000 title abstract 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims abstract description 112
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims abstract description 58
- 235000012754 curcumin Nutrition 0.000 claims abstract description 56
- 229940109262 curcumin Drugs 0.000 claims abstract description 56
- 239000004148 curcumin Substances 0.000 claims abstract description 56
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims abstract description 56
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims abstract description 55
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims abstract description 55
- 235000021283 resveratrol Nutrition 0.000 claims abstract description 55
- 229940016667 resveratrol Drugs 0.000 claims abstract description 55
- 240000000950 Hippophae rhamnoides Species 0.000 claims abstract description 42
- 235000003145 Hippophae rhamnoides Nutrition 0.000 claims abstract description 41
- 229930187719 Soyasaponin Natural products 0.000 claims abstract description 40
- 235000013305 food Nutrition 0.000 claims abstract description 38
- 239000000284 extract Substances 0.000 claims abstract description 36
- 235000011430 Malus pumila Nutrition 0.000 claims abstract description 33
- 235000015103 Malus silvestris Nutrition 0.000 claims abstract description 33
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 31
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 31
- 150000008442 polyphenolic compounds Chemical class 0.000 claims abstract description 30
- 235000010413 sodium alginate Nutrition 0.000 claims abstract description 30
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims abstract description 29
- 229960004488 linolenic acid Drugs 0.000 claims abstract description 29
- 239000000661 sodium alginate Substances 0.000 claims abstract description 28
- 229940005550 sodium alginate Drugs 0.000 claims abstract description 28
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims abstract description 27
- 238000004519 manufacturing process Methods 0.000 claims abstract description 6
- 238000004806 packaging method and process Methods 0.000 claims abstract description 5
- 238000003756 stirring Methods 0.000 claims abstract description 5
- 150000002632 lipids Chemical class 0.000 claims description 51
- 239000003814 drug Substances 0.000 claims description 41
- 244000241838 Lycium barbarum Species 0.000 claims description 38
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 38
- 239000003795 chemical substances by application Substances 0.000 claims description 25
- 238000004040 coloring Methods 0.000 claims description 25
- 244000037364 Cinnamomum aromaticum Species 0.000 claims description 23
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims description 23
- 235000020717 hawthorn extract Nutrition 0.000 claims description 13
- 239000002994 raw material Substances 0.000 claims description 13
- 235000015468 Lycium chinense Nutrition 0.000 claims description 11
- 210000004185 liver Anatomy 0.000 abstract description 64
- 235000019197 fats Nutrition 0.000 abstract description 53
- 240000000171 Crataegus monogyna Species 0.000 abstract description 34
- 235000009917 Crataegus X brevipes Nutrition 0.000 abstract description 33
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 abstract description 33
- 235000009685 Crataegus X maligna Nutrition 0.000 abstract description 33
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 abstract description 33
- 235000009486 Crataegus bullatus Nutrition 0.000 abstract description 33
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 abstract description 33
- 235000009682 Crataegus limnophila Nutrition 0.000 abstract description 33
- 235000004423 Crataegus monogyna Nutrition 0.000 abstract description 33
- 235000002313 Crataegus paludosa Nutrition 0.000 abstract description 33
- 235000009840 Crataegus x incaedua Nutrition 0.000 abstract description 33
- 230000036772 blood pressure Effects 0.000 abstract description 19
- 239000008103 glucose Substances 0.000 abstract description 16
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 14
- 230000017531 blood circulation Effects 0.000 abstract description 13
- 239000000463 material Substances 0.000 abstract description 13
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 12
- 241000196324 Embryophyta Species 0.000 abstract description 12
- 206010061218 Inflammation Diseases 0.000 abstract description 12
- 230000004054 inflammatory process Effects 0.000 abstract description 12
- 210000003734 kidney Anatomy 0.000 abstract description 12
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 11
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 8
- 230000001737 promoting effect Effects 0.000 abstract description 8
- 208000007536 Thrombosis Diseases 0.000 abstract description 7
- 235000013376 functional food Nutrition 0.000 abstract description 7
- 238000002156 mixing Methods 0.000 abstract description 5
- 201000001320 Atherosclerosis Diseases 0.000 abstract description 3
- 241000037831 Polygonatum sibiricum Species 0.000 abstract 1
- 238000007689 inspection Methods 0.000 abstract 1
- 229940026314 red yeast rice Drugs 0.000 abstract 1
- 230000002040 relaxant effect Effects 0.000 abstract 1
- 210000000582 semen Anatomy 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 154
- 230000000694 effects Effects 0.000 description 146
- 238000011160 research Methods 0.000 description 66
- 239000003925 fat Substances 0.000 description 57
- 235000012000 cholesterol Nutrition 0.000 description 56
- 241000699666 Mus <mouse, genus> Species 0.000 description 44
- 206010012601 diabetes mellitus Diseases 0.000 description 41
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 38
- 241000700159 Rattus Species 0.000 description 37
- 230000006870 function Effects 0.000 description 37
- 210000002966 serum Anatomy 0.000 description 37
- 230000001077 hypotensive effect Effects 0.000 description 33
- 210000004027 cell Anatomy 0.000 description 31
- 230000002218 hypoglycaemic effect Effects 0.000 description 31
- 150000003626 triacylglycerols Chemical class 0.000 description 28
- 208000001953 Hypotension Diseases 0.000 description 27
- 208000021822 hypotensive Diseases 0.000 description 27
- 230000002401 inhibitory effect Effects 0.000 description 25
- 230000015572 biosynthetic process Effects 0.000 description 24
- 241000283973 Oryctolagus cuniculus Species 0.000 description 22
- 230000004224 protection Effects 0.000 description 21
- 102000004877 Insulin Human genes 0.000 description 20
- 108090001061 Insulin Proteins 0.000 description 20
- 229940125396 insulin Drugs 0.000 description 20
- 239000000126 substance Substances 0.000 description 20
- 230000003110 anti-inflammatory effect Effects 0.000 description 19
- 239000003963 antioxidant agent Substances 0.000 description 19
- 235000006708 antioxidants Nutrition 0.000 description 19
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 19
- 230000003078 antioxidant effect Effects 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 18
- -1 lipid peroxide Chemical class 0.000 description 18
- 150000003254 radicals Chemical class 0.000 description 18
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 17
- 239000000203 mixture Substances 0.000 description 17
- 210000004204 blood vessel Anatomy 0.000 description 16
- 229930003944 flavone Natural products 0.000 description 16
- 235000011949 flavones Nutrition 0.000 description 16
- 230000009102 absorption Effects 0.000 description 15
- 238000010521 absorption reaction Methods 0.000 description 15
- 238000003786 synthesis reaction Methods 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 14
- 230000002265 prevention Effects 0.000 description 14
- 230000003064 anti-oxidating effect Effects 0.000 description 13
- 230000008859 change Effects 0.000 description 13
- 230000007423 decrease Effects 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- 230000001681 protective effect Effects 0.000 description 13
- 102000004190 Enzymes Human genes 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 12
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 12
- 229940088598 enzyme Drugs 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 239000001301 oxygen Substances 0.000 description 12
- 229910052760 oxygen Inorganic materials 0.000 description 12
- 230000000144 pharmacologic effect Effects 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 210000000952 spleen Anatomy 0.000 description 12
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 12
- 108010007622 LDL Lipoproteins Proteins 0.000 description 11
- 102000007330 LDL Lipoproteins Human genes 0.000 description 11
- 206010028980 Neoplasm Diseases 0.000 description 11
- 208000008589 Obesity Diseases 0.000 description 11
- 230000009471 action Effects 0.000 description 11
- 230000006378 damage Effects 0.000 description 11
- 230000036039 immunity Effects 0.000 description 11
- 230000007246 mechanism Effects 0.000 description 11
- 230000004060 metabolic process Effects 0.000 description 11
- 235000020824 obesity Nutrition 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 10
- 201000005577 familial hyperlipidemia Diseases 0.000 description 10
- 150000002212 flavone derivatives Chemical class 0.000 description 10
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 10
- 210000002216 heart Anatomy 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 208000031226 Hyperlipidaemia Diseases 0.000 description 9
- 108010028554 LDL Cholesterol Proteins 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 208000034189 Sclerosis Diseases 0.000 description 9
- 206010039966 Senile dementia Diseases 0.000 description 9
- 210000001367 artery Anatomy 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 9
- 239000000194 fatty acid Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 230000028327 secretion Effects 0.000 description 9
- 210000002784 stomach Anatomy 0.000 description 9
- 206010020772 Hypertension Diseases 0.000 description 8
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 230000002785 anti-thrombosis Effects 0.000 description 8
- 230000000840 anti-viral effect Effects 0.000 description 8
- 239000003146 anticoagulant agent Substances 0.000 description 8
- 210000001772 blood platelet Anatomy 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 235000009508 confectionery Nutrition 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- 238000007254 oxidation reaction Methods 0.000 description 8
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 8
- 210000002381 plasma Anatomy 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- DSCFFEYYQKSRSV-FIZWYUIZSA-N (-)-Quebrachitol Chemical compound CO[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@H]1O DSCFFEYYQKSRSV-FIZWYUIZSA-N 0.000 description 7
- DSCFFEYYQKSRSV-UHFFFAOYSA-N 1L-O1-methyl-muco-inositol Natural products COC1C(O)C(O)C(O)C(O)C1O DSCFFEYYQKSRSV-UHFFFAOYSA-N 0.000 description 7
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- 229930003268 Vitamin C Natural products 0.000 description 7
- 210000001789 adipocyte Anatomy 0.000 description 7
- 230000008485 antagonism Effects 0.000 description 7
- 150000004676 glycans Chemical class 0.000 description 7
- 230000036737 immune function Effects 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 230000003647 oxidation Effects 0.000 description 7
- 230000000242 pagocytic effect Effects 0.000 description 7
- 229920001282 polysaccharide Polymers 0.000 description 7
- 239000005017 polysaccharide Substances 0.000 description 7
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 7
- 230000001629 suppression Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 235000019154 vitamin C Nutrition 0.000 description 7
- 239000011718 vitamin C Substances 0.000 description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- 108010010234 HDL Lipoproteins Proteins 0.000 description 6
- 102000015779 HDL Lipoproteins Human genes 0.000 description 6
- IOUVKUPGCMBWBT-DARKYYSBSA-N Phloridzin Natural products O[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 IOUVKUPGCMBWBT-DARKYYSBSA-N 0.000 description 6
- IIXHQGSINFQLRR-UHFFFAOYSA-N Piceatannol Natural products Oc1ccc(C=Cc2c(O)c(O)c3CCCCc3c2O)cc1O IIXHQGSINFQLRR-UHFFFAOYSA-N 0.000 description 6
- 230000000844 anti-bacterial effect Effects 0.000 description 6
- 230000002929 anti-fatigue Effects 0.000 description 6
- 210000004351 coronary vessel Anatomy 0.000 description 6
- 230000029142 excretion Effects 0.000 description 6
- 230000004438 eyesight Effects 0.000 description 6
- 238000003304 gavage Methods 0.000 description 6
- 230000002440 hepatic effect Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000010534 mechanism of action Effects 0.000 description 6
- 208000031225 myocardial ischemia Diseases 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- IOUVKUPGCMBWBT-UHFFFAOYSA-N phloridzosid Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 IOUVKUPGCMBWBT-UHFFFAOYSA-N 0.000 description 6
- IOUVKUPGCMBWBT-QNDFHXLGSA-N phlorizin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 IOUVKUPGCMBWBT-QNDFHXLGSA-N 0.000 description 6
- 235000019139 phlorizin Nutrition 0.000 description 6
- CDRPUGZCRXZLFL-OWOJBTEDSA-N piceatannol Chemical compound OC1=CC(O)=CC(\C=C\C=2C=C(O)C(O)=CC=2)=C1 CDRPUGZCRXZLFL-OWOJBTEDSA-N 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 235000020095 red wine Nutrition 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 230000002000 scavenging effect Effects 0.000 description 6
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 6
- LBTVHXHERHESKG-UHFFFAOYSA-N tetrahydrocurcumin Chemical compound C1=C(O)C(OC)=CC(CCC(=O)CC(=O)CCC=2C=C(OC)C(O)=CC=2)=C1 LBTVHXHERHESKG-UHFFFAOYSA-N 0.000 description 6
- 102000009123 Fibrin Human genes 0.000 description 5
- 108010073385 Fibrin Proteins 0.000 description 5
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 229930014669 anthocyanidin Natural products 0.000 description 5
- 150000001452 anthocyanidin derivatives Chemical class 0.000 description 5
- 235000008758 anthocyanidins Nutrition 0.000 description 5
- 230000003712 anti-aging effect Effects 0.000 description 5
- 230000003266 anti-allergic effect Effects 0.000 description 5
- 230000001093 anti-cancer Effects 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 229960003237 betaine Drugs 0.000 description 5
- 208000029078 coronary artery disease Diseases 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 201000006549 dyspepsia Diseases 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 208000010706 fatty liver disease Diseases 0.000 description 5
- 229950003499 fibrin Drugs 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 229910001385 heavy metal Inorganic materials 0.000 description 5
- 201000001421 hyperglycemia Diseases 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 230000002503 metabolic effect Effects 0.000 description 5
- 210000004165 myocardium Anatomy 0.000 description 5
- 230000035790 physiological processes and functions Effects 0.000 description 5
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 5
- 230000000630 rising effect Effects 0.000 description 5
- 229930182490 saponin Natural products 0.000 description 5
- 150000007949 saponins Chemical class 0.000 description 5
- 238000005728 strengthening Methods 0.000 description 5
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 4
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 4
- 108010082126 Alanine transaminase Proteins 0.000 description 4
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 108091006146 Channels Proteins 0.000 description 4
- 208000004930 Fatty Liver Diseases 0.000 description 4
- 108010023302 HDL Cholesterol Proteins 0.000 description 4
- 206010019708 Hepatic steatosis Diseases 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- 206010021143 Hypoxia Diseases 0.000 description 4
- 102100031455 NAD-dependent protein deacetylase sirtuin-1 Human genes 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- 208000004880 Polyuria Diseases 0.000 description 4
- 108010041191 Sirtuin 1 Proteins 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 4
- 230000002744 anti-aggregatory effect Effects 0.000 description 4
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 4
- 230000003143 atherosclerotic effect Effects 0.000 description 4
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 4
- 239000003613 bile acid Substances 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 230000000916 dilatatory effect Effects 0.000 description 4
- 230000035619 diuresis Effects 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 150000002213 flavones Chemical class 0.000 description 4
- 229930003935 flavonoid Natural products 0.000 description 4
- 150000002215 flavonoids Chemical class 0.000 description 4
- 235000017173 flavonoids Nutrition 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 231100000753 hepatic injury Toxicity 0.000 description 4
- 230000004727 humoral immunity Effects 0.000 description 4
- 239000000413 hydrolysate Substances 0.000 description 4
- 206010020718 hyperplasia Diseases 0.000 description 4
- 230000003859 lipid peroxidation Effects 0.000 description 4
- 210000005229 liver cell Anatomy 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 230000000291 postprandial effect Effects 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 210000001541 thymus gland Anatomy 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- VDFKKLMKUNQLDX-UHFFFAOYSA-N 1,1-dimethylhydrazine;1,2-dimethylhydrazine Chemical class CNNC.CN(C)N VDFKKLMKUNQLDX-UHFFFAOYSA-N 0.000 description 3
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 3
- 229920002527 Glycogen Polymers 0.000 description 3
- 241000229143 Hippophae Species 0.000 description 3
- 235000003935 Hippophae Nutrition 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 102000015696 Interleukins Human genes 0.000 description 3
- 108010063738 Interleukins Proteins 0.000 description 3
- 102000004895 Lipoproteins Human genes 0.000 description 3
- 108090001030 Lipoproteins Proteins 0.000 description 3
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 3
- 208000001280 Prediabetic State Diseases 0.000 description 3
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 description 3
- 102000019197 Superoxide Dismutase Human genes 0.000 description 3
- 108010012715 Superoxide dismutase Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 206010003119 arrhythmia Diseases 0.000 description 3
- 230000004872 arterial blood pressure Effects 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 230000003915 cell function Effects 0.000 description 3
- 230000007969 cellular immunity Effects 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 229940096919 glycogen Drugs 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 235000009200 high fat diet Nutrition 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 230000037356 lipid metabolism Effects 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 3
- 229960004844 lovastatin Drugs 0.000 description 3
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 3
- 230000037323 metabolic rate Effects 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 210000003024 peritoneal macrophage Anatomy 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 201000009104 prediabetes syndrome Diseases 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 229920002414 procyanidin Polymers 0.000 description 3
- 239000002689 soil Substances 0.000 description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 description 3
- 108091035539 telomere Proteins 0.000 description 3
- 210000003411 telomere Anatomy 0.000 description 3
- 102000055501 telomere Human genes 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 3
- 150000003648 triterpenes Chemical class 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- 235000014101 wine Nutrition 0.000 description 3
- XFZJEEAOWLFHDH-UHFFFAOYSA-N (2R,2'R,3R,3'R,4R)-3,3',4',5,7-Pentahydroxyflavan(48)-3,3',4',5,7-pentahydroxyflavan Natural products C=12OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C(O)C=C(O)C=1C(C1=C(O)C=C(O)C=C1O1)C(O)C1C1=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-UHFFFAOYSA-N 0.000 description 2
- JLTCWSBVQSZVLT-CDIPANDDSA-N (2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1.C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 JLTCWSBVQSZVLT-CDIPANDDSA-N 0.000 description 2
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 206010048799 Acute generalised exanthematous pustulosis Diseases 0.000 description 2
- 208000005441 Acute generalized exanthematous pustulosis Diseases 0.000 description 2
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 2
- YDQWDHRMZQUTBA-UHFFFAOYSA-N Aloe emodin Chemical compound C1=CC=C2C(=O)C3=CC(CO)=CC(O)=C3C(=O)C2=C1O YDQWDHRMZQUTBA-UHFFFAOYSA-N 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 101800004538 Bradykinin Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 244000201986 Cassia tora Species 0.000 description 2
- 235000014552 Cassia tora Nutrition 0.000 description 2
- 208000002177 Cataract Diseases 0.000 description 2
- 206010008570 Chloasma Diseases 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- 208000031404 Chromosome Aberrations Diseases 0.000 description 2
- 235000003392 Curcuma domestica Nutrition 0.000 description 2
- 244000008991 Curcuma longa Species 0.000 description 2
- 230000005778 DNA damage Effects 0.000 description 2
- 231100000277 DNA damage Toxicity 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- 206010012655 Diabetic complications Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 2
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010061998 Hepatic lesion Diseases 0.000 description 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 2
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 108010061833 Integrases Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102100035792 Kininogen-1 Human genes 0.000 description 2
- 208000000501 Lipidoses Diseases 0.000 description 2
- 206010024585 Lipidosis Diseases 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 208000003351 Melanosis Diseases 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 241000756042 Polygonatum Species 0.000 description 2
- 235000008737 Polygonatum biflorum Nutrition 0.000 description 2
- 102000005320 Posterior Pituitary Hormones Human genes 0.000 description 2
- 108010070873 Posterior Pituitary Hormones Proteins 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- MOJZMWJRUKIQGL-FWCKPOPSSA-N Procyanidin C2 Natural products O[C@@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c([C@H]3[C@H](O)[C@@H](c4cc(O)c(O)cc4)Oc4c3c(O)cc(O)c4)c(O)cc(O)c2[C@@H]1c1c(O)cc(O)c2c1O[C@@H]([C@H](O)C2)c1cc(O)c(O)cc1 MOJZMWJRUKIQGL-FWCKPOPSSA-N 0.000 description 2
- 102000007156 Resistin Human genes 0.000 description 2
- 108010047909 Resistin Proteins 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- 235000009754 Vitis X bourquina Nutrition 0.000 description 2
- 235000012333 Vitis X labruscana Nutrition 0.000 description 2
- 240000006365 Vitis vinifera Species 0.000 description 2
- 235000014787 Vitis vinifera Nutrition 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 229960000711 alprostadil Drugs 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 150000004056 anthraquinones Chemical class 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- RNXZPKOEJUFJON-UHFFFAOYSA-N aurantio-obtusin Chemical compound CC1=C(O)C(OC)=C2C(=O)C3=C(O)C(OC)=C(O)C=C3C(=O)C2=C1 RNXZPKOEJUFJON-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 231100000005 chromosome aberration Toxicity 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 238000002485 combustion reaction Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 235000003373 curcuma longa Nutrition 0.000 description 2
- 235000021438 curry Nutrition 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000004626 essential fatty acids Nutrition 0.000 description 2
- 208000030533 eye disease Diseases 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000000762 glandular Effects 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 230000002443 hepatoprotective effect Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000000401 methanolic extract Substances 0.000 description 2
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 229960005489 paracetamol Drugs 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 238000005502 peroxidation Methods 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- FFWOKTFYGVYKIR-UHFFFAOYSA-N physcion Chemical compound C1=C(C)C=C2C(=O)C3=CC(OC)=CC(O)=C3C(=O)C2=C1O FFWOKTFYGVYKIR-UHFFFAOYSA-N 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 230000007505 plaque formation Effects 0.000 description 2
- HGVVOUNEGQIPMS-UHFFFAOYSA-N procyanidin Chemical compound O1C2=CC(O)=CC(O)=C2C(O)C(O)C1(C=1C=C(O)C(O)=CC=1)OC1CC2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 HGVVOUNEGQIPMS-UHFFFAOYSA-N 0.000 description 2
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 230000036186 satiety Effects 0.000 description 2
- 235000019627 satiety Nutrition 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 102000014898 transaminase activity proteins Human genes 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 235000013976 turmeric Nutrition 0.000 description 2
- XUARCIYIVXVTAE-ZAPOICBTSA-N uvaol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(CO)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C XUARCIYIVXVTAE-ZAPOICBTSA-N 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 108010051913 15-hydroxyprostaglandin dehydrogenase Proteins 0.000 description 1
- 102100030489 15-hydroxyprostaglandin dehydrogenase [NAD(+)] Human genes 0.000 description 1
- XFSBVAOIAHNAPC-XTHSEXKGSA-N 16-Ethyl-1alpha,6alpha,19beta-trimethoxy-4-(methoxymethyl)-aconitane-3alpha,8,10alpha,11,18alpha-pentol, 8-acetate 10-benzoate Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@@]45C6[C@@H]([C@@]([C@H]31)(OC(C)=O)[C@@H](O)[C@@H]2OC)[C@H](OC)[C@@H]4[C@]([C@@H](C[C@@H]5OC)O)(COC)CN6CC)C(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-XTHSEXKGSA-N 0.000 description 1
- ADVGKWPZRIDURE-UHFFFAOYSA-N 2'-Hydroxyacetanilide Chemical compound CC(=O)NC1=CC=CC=C1O ADVGKWPZRIDURE-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- XFSBVAOIAHNAPC-UHFFFAOYSA-N Aconitin Natural products CCN1CC(C(CC2OC)O)(COC)C3C(OC)C(C(C45)(OC(C)=O)C(O)C6OC)C1C32C4CC6(O)C5OC(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-UHFFFAOYSA-N 0.000 description 1
- 102000005869 Activating Transcription Factors Human genes 0.000 description 1
- 108010005254 Activating Transcription Factors Proteins 0.000 description 1
- 102100036664 Adenosine deaminase Human genes 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 1
- 102000011690 Adiponectin Human genes 0.000 description 1
- 108010076365 Adiponectin Proteins 0.000 description 1
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 102000005862 Angiotensin II Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 102100040202 Apolipoprotein B-100 Human genes 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 102100032752 C-reactive protein Human genes 0.000 description 1
- 101710186200 CCAAT/enhancer-binding protein Proteins 0.000 description 1
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 208000001378 Carbon Tetrachloride Poisoning Diseases 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- SBVZTBIAKFTNIJ-CZNQJBLBSA-N Cassiaside Chemical compound C1=CC=C2C=C3OC(C)=CC(=O)C3=C(O)C2=C1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SBVZTBIAKFTNIJ-CZNQJBLBSA-N 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 208000018152 Cerebral disease Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 208000022306 Cerebral injury Diseases 0.000 description 1
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 206010009208 Cirrhosis alcoholic Diseases 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- 241000530115 Clerodendrum trichotomum Species 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 229920002911 Colestipol Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 244000160089 Crataegus cuneata Species 0.000 description 1
- 235000008440 Crataegus cuneata Nutrition 0.000 description 1
- 235000014283 Crataegus pinnatifida var major Nutrition 0.000 description 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 108010088106 Dihydrouracil Dehydrogenase (NAD+) Proteins 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 241001480035 Epidermophyton Species 0.000 description 1
- 208000007530 Essential hypertension Diseases 0.000 description 1
- 235000014066 European mistletoe Nutrition 0.000 description 1
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 101000889953 Homo sapiens Apolipoprotein B-100 Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 206010010164 Hypertension complications Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- UGNZSMZSJYOGNX-UHFFFAOYSA-N Isoviocristine Natural products O=C1C=C(C)C(=O)C2=CC3=CC(OC)=CC(O)=C3C(O)=C21 UGNZSMZSJYOGNX-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 235000002322 Monascus purpureus Nutrition 0.000 description 1
- 244000113306 Monascus purpureus Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 101000654471 Mus musculus NAD-dependent protein deacetylase sirtuin-1 Proteins 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- 206010050106 Paroxysmal arrhythmia Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 1
- 244000179560 Prunella vulgaris Species 0.000 description 1
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 206010057430 Retinal injury Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 244000153955 Reynoutria sachalinensis Species 0.000 description 1
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 description 1
- 244000152640 Rhipsalis cassutha Species 0.000 description 1
- 235000012300 Rhipsalis cassutha Nutrition 0.000 description 1
- 235000000533 Rosa gallica Nutrition 0.000 description 1
- 244000181025 Rosa gallica Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 241000607764 Shigella dysenteriae Species 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 241000208292 Solanaceae Species 0.000 description 1
- 244000062793 Sorghum vulgare Species 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 108010074506 Transfer Factor Proteins 0.000 description 1
- 241000893963 Trichophyton concentricum Species 0.000 description 1
- 241000223229 Trichophyton rubrum Species 0.000 description 1
- 240000000851 Vaccinium corymbosum Species 0.000 description 1
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- 208000035868 Vascular inflammations Diseases 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 101710097943 Viral-enhancing factor Proteins 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 241000234314 Zingiber Species 0.000 description 1
- CEDLUJHGAQHWKL-UHFFFAOYSA-N [C].ClC(Cl)(Cl)Cl Chemical compound [C].ClC(Cl)(Cl)Cl CEDLUJHGAQHWKL-UHFFFAOYSA-N 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 229940039750 aconitine Drugs 0.000 description 1
- STDXGNLCJACLFY-UHFFFAOYSA-N aconitine Natural products CCN1CC2(COC)C(O)CC(O)C34C5CC6(O)C(OC)C(O)C(OC(=O)C)(C5C6OC(=O)c7ccccc7)C(C(OC)C23)C14 STDXGNLCJACLFY-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 1
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 108010065394 aminopherase Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000002416 angiotensin derivative Substances 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- WLXGUTUUWXVZNM-UHFFFAOYSA-N anthraglycoside A Natural products C1=C(C)C=C2C(=O)C3=CC(OC)=CC(O)=C3C(=O)C2=C1OC1OC(CO)C(O)C(O)C1O WLXGUTUUWXVZNM-UHFFFAOYSA-N 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 230000001466 anti-adreneric effect Effects 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000003217 anti-cancerogenic effect Effects 0.000 description 1
- 230000001194 anti-hemostatic effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000002402 anti-lipaemic effect Effects 0.000 description 1
- 230000002223 anti-pathogen Effects 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 208000003464 asthenopia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 235000021014 blueberries Nutrition 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000002368 cardiac glycoside Substances 0.000 description 1
- 229940097217 cardiac glycoside Drugs 0.000 description 1
- 239000000496 cardiotonic agent Substances 0.000 description 1
- OXLQCHMJDJSJKF-UHFFFAOYSA-N cassiaside Natural products C1=C(O)C=C2C=C3OC(C)=CC(=O)C3=C(O)C2=C1OC1OC(CO)C(O)C(O)C1O OXLQCHMJDJSJKF-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000004098 cellular respiration Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 235000005513 chalcones Nutrition 0.000 description 1
- 150000001789 chalcones Chemical class 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- 230000002279 cholagogic effect Effects 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 229940097479 colestid Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- MDZKJHQSJHYOHJ-UHFFFAOYSA-N crataegolic acid Natural products C1C(O)C(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MDZKJHQSJHYOHJ-UHFFFAOYSA-N 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 210000000695 crystalline len Anatomy 0.000 description 1
- 208000030381 cutaneous melanoma Diseases 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- PXLWOFBAEVGBOA-UHFFFAOYSA-N dihydrochalcone Natural products OC1C(O)C(O)C(CO)OC1C1=C(O)C=CC(C(=O)CC(O)C=2C=CC(O)=CC=2)=C1O PXLWOFBAEVGBOA-UHFFFAOYSA-N 0.000 description 1
- 125000005594 diketone group Chemical group 0.000 description 1
- WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 150000002216 flavonol derivatives Chemical class 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- IXZISFNWUWKBOM-ARQDHWQXSA-N fructosamine Chemical compound NC[C@@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O IXZISFNWUWKBOM-ARQDHWQXSA-N 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 238000002309 gasification Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 230000003516 hyperlipidaemic effect Effects 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 238000005213 imbibition Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 101150044508 key gene Proteins 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 229960004232 linoleic acid Drugs 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 229940040461 lipase Drugs 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002189 macula lutea Anatomy 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- MDZKJHQSJHYOHJ-LLICELPBSA-N maslinic acid Chemical compound C1[C@@H](O)[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MDZKJHQSJHYOHJ-LLICELPBSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 235000019713 millet Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 229940057059 monascus purpureus Drugs 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- GACQNVJDWUAPFY-UHFFFAOYSA-N n'-[2-[2-(2-aminoethylamino)ethylamino]ethyl]ethane-1,2-diamine;hydrochloride Chemical compound Cl.NCCNCCNCCNCCN GACQNVJDWUAPFY-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000008557 oxygen metabolism Effects 0.000 description 1
- 229940098695 palmitic acid Drugs 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 239000001335 perilla frutescens leaf extract Substances 0.000 description 1
- 230000036513 peripheral conductance Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 229940090007 persantine Drugs 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 125000004402 polyphenol group Chemical group 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000019525 primary metabolic process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 229910052701 rubidium Inorganic materials 0.000 description 1
- IGLNJRXAVVLDKE-UHFFFAOYSA-N rubidium atom Chemical compound [Rb] IGLNJRXAVVLDKE-UHFFFAOYSA-N 0.000 description 1
- NWMIYTWHUDFRPL-UHFFFAOYSA-N sapogenin Natural products COC(=O)C1(CO)C(O)CCC2(C)C1CCC3(C)C2CC=C4C5C(C)(O)C(C)CCC5(CCC34C)C(=O)O NWMIYTWHUDFRPL-UHFFFAOYSA-N 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 235000008113 selfheal Nutrition 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 229940007046 shigella dysenteriae Drugs 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000000192 social effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 229930002534 steroid glycoside Natural products 0.000 description 1
- 150000005856 steroid saponins Chemical class 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical class C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 108010050939 thrombocytin Proteins 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- SYFNOXYZEIYOSE-UHFFFAOYSA-N uvaol Natural products CC1CCC2(O)CCC3(C)C(=CCC4(C)C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C SYFNOXYZEIYOSE-UHFFFAOYSA-N 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000001196 vasorelaxation Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 208000003663 ventricular fibrillation Diseases 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- DTOSIQBPPRVQHS-UHFFFAOYSA-N α-Linolenic acid Chemical compound CCC=CCC=CCC=CCCCCCCCC(O)=O DTOSIQBPPRVQHS-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P30/00—Shaping or working of foodstuffs characterised by the process or apparatus
- A23P30/20—Extruding
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Manufacturing & Machinery (AREA)
- Botany (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明属于功能食品或保健食品,尤以青藏高原天然无污染优质药食两用植物黑枸杞提取物、沙棘提取物、黄精提取物、山楂提取物、决明子提取物、红曲、白藜芦醇、姜黄素、苹果多酚、α-亚麻酸、大豆皂甙、海藻酸钠等原料制成的功能食品或保健食品,具有滋补肝肾、活血化瘀等功效。用于降血脂、降血压、降血糖、减肥、抗炎、通便、保护肝脏、抗动脉粥样硬化、抗血栓、防治心脑血管疾病等功效,该产品制作工艺:原料混合、搅拌、压片、检验合格,包装成为正式产品。
Description
一、技术领域:本发明属于功能食品或保健食品,尤以青藏高原天然无污染优质药食两用植物黑枸杞、沙棘、黄精、山楂、决明子、红曲、白藜芦醇、姜黄素、苹果多酚、α-亚麻酸、大豆皂甙、海藻酸钠等原料,采用现代先进工艺加工而成的功能食品或保健食品。
二、背景技术:本发明以黑枸杞、沙棘、黄精、山楂、决明子、红曲、白藜芦醇、姜黄素、苹果多酚、α-亚麻酸、大豆皂甙、海藻酸钠等原料制成的功能食品或保健食品。具有滋补肝肾、活血化瘀等功效。用于降血脂、降血压、降血糖、减肥、抗炎、通便、保护肝脏、抗动脉粥样硬化、抗血栓、防治心脑血管疾病等功效。目前市场上还没有同类产品,创新研发该产品可为给高脂血症等心脑血管疾病患者提供了一种新产品。该产品以纯天然药食两用植物为原料制成的片剂,无任何毒副作用,纯度高、活性强、易吸收利用、服用方便、效果明显。
三、发明内容:高血脂症是指各种原因导致的血清中胆固醇和甘油三酯水平升高的一类不良生活方式为主的疾病。随着我国经济的快速发展,国民的生活水平不断提高,饮食结构和生活方式也发生了变化,导致人体血脂的异常率呈现不断的上升趋势。研究表明,高脂血症是导致动脉粥样硬化,心绞痛,心肌梗死,脑梗塞及肾损伤等心脑血管疾病的独立危险因素。据权威部门的统计数字显示,我国血脂异常患者率为18.6%,18岁以上高脂血症患病人数已达到2亿多,并成逐年上升的趋势,创新研发本品可有效控制高脂血症的上升,对治胃病具有重要的社会意义和经济效益。
四、原料配方:黑枸杞提取物50千克、沙棘提取物30千克、黄精提取物50千克、山楂提取物30千克、决明子提取物30千克、红曲100千克、白藜芦醇20千克、姜黄素10千克、苹果多酚60千克、α-亚麻酸60千克、大豆皂甙20千克、海藻酸钠50千克为原料。
五、技术方案
(一)、黑枸杞提取物:(Lyciam barbarnm extraat),黑枸杞是生长在青藏高原绿色生态环境,纯天然珍品药食两用植物黑枸杞干燥果实。黑枸杞是一种稀有珍贵的原生态高端滋补品。黑枸杞为茄科植物枸杞成熟果实。性平,味甘。归肝、肾经。具有滋补肝肾、益精明目、润肺的功效。用于虚劳精亏、腰膝酸痛、眩晕耳鸣、内热消渴、血虚萎黄、提高视力、目昏不明等。现代医学研究认为,黑枸杞具有增强免疫力、抗疲劳、降血压、降血脂、降血糖、保护肝脏、减肥、抗衰老、抗癌等功能。
化学成分:黑枸杞含多糖、氨基酸、甜菜碱、胡萝卜素、维生素B、维生素C、烟酸等多种维生素以及锰、铬、锌、铜、镁、钙、锗、钴等微量元素。而且还有丰富的天然原花青素,其中原花青素含量是蓝莓含量的数倍,是迄今为止发现原花青素含量最高的天然野生植物。
药理作用:1、增强免疫力:小鼠灌服水提取物或肌注醇提取物均能显著增强其网状内皮系统对印度墨汁的吞噬能力。水提取物或枸杞多糖均能促进小鼠腹腔巨噬细胞吞噬功能和血清中溶菌酶活性。给正常或老年小鼠灌服或腹枸杞多糖,能显著增强腹腔巨噬细胞c3b和Fc的受体数和活力,可使老年小鼠抑制性T细胞调节抗体功能恢复到成年小鼠的水平。黑枸杞多糖纯品比粗品具有更显著的免疫应答效应,各项免疫指标(包括非特异性免疫的免疫器官质量、巨噬细胞吞噬作用、特异性体液免疫的血清溶血素,特异性细胞免疫中的退发型变态反应、淋巴细胞转化率、E玫瑰花结形成等)均有显著的差异。
2、保护肝脏、抗脂肪肝:黑枸杞提取物对保护肝脏和抗脂肪肝具有一定的作用。现代医学研究发现,黑枸杞中含有一种有效成分一甜菜碱,它对治疗肝脏疾病很有效。实验表明,甜菜碱有抑制脂肪在肝细胞内沉积,促进肝细胞再生的作用。另外,黑枸杞的中甜菜碱能防止肝脏内过多的脂肪贮存,有防脂肪肝的作用,据报道,长期经大鼠饲喂水提取物或甜菜碱饲料对ccl4引起的肝损害有保护作用,能明显降低转氨酶及肝中脂质的变化,可抑制肝中脂质沉积及促进肝细胞新生,对肝脏脂质过氧化损伤有明显的保护作用。
3、降血脂、防治动脉硬化:黑枸杞提取物动物及临床实验均具有良好的降血脂作用。多糖对高血脂家兔的血脂有明显的作用,能明显降低血清胆固醇及三酰甘油的含量。黑枸杞还可降低大鼠血胆固醇,并明显抑制灌喂胆固醇和猪油的家兔血清胆固醇升高,还具有抗动脉硬化的作用。黑枸杞中富含原花青素具有显著的降血脂和胆固醇作用,据国内报道,动物实验结果显示,果实中的花青素能显著降低饲用高胆固醇饲料大鼠血清中总胆固醇、甘油三酯和低密度脂蛋白胆固醇及低密度脂蛋白的含量,同时测定大鼠粪便中胆固醇,结果表明,黑枸杞原花青素能阻止消化道对胆固醇的吸收,因此,在高脂饮食大鼠粪便中出现大量的胆固醇。另有实验结果显示,喂养含原花青素饲料的雄性大鼠6周后,大鼠血清和肝脏中的甘油三酯和胆固醇均有下降34.4%和18.1%,其作用机制是原花青素能够增强肝脏CYP7AI的活性和表达,促进胆固醇向胆汁酸转化,通过增强胆汁酸的有效排泄而降低血液总胆固醇水平。据国外报道,意大利科学家研究发现,含有原花青素的水果有助于降低胆固醇水平。研究人员选取了一组志愿者每天食用含有原花青素的果实1个月,结果显示,这些志愿者的总胆固醇水平、低密度脂蛋白和甘油三酯的含量分别下降8.78%、13.73%和22.8%。研究认为,富含原花青素的果实能加速体内胆固醇的分解并降低脂密度脂蛋白、抗血管硬化的作用,从而防治心血管和脑中风的发生。
4、降血压和保护心脑血管:血管中的弹性纤维逐渐氧化变硬,是导致高血压的主要原因。黑枸杞所含的原花青素,可通过提高血管弹性而降低血压。实验证明,黑枸杞提取物能降低血液中胆固醇水平,减少血管壁上胆固醇沉积及抑制血管紧张素酶活性来降低血压。另有研究,在大鼠饲料中添加黑枸杞提取物、铬、锌成分,而实验组血压明显低于对照组,其机理是黑枸杞提取物降低了自由基的形成,改善胰岛素的敏感性。
5、抗氧化:黑枸杞具有良好的抗氧化作用。黑枸杞含有丰富的原花青素,能抑制血浆中的脂质过氧化自由基生成作用,又能阻断脂质过氧化作用。在保护DNA、蛋白质和膜结构免遭氧化损伤起着重要作用,已知人体晶状体、角膜及玻璃体中的超氧化物歧化酶活性低,老年人血浆和组织,这是一种维持机制减弱,可能是老年人血浆过氧化脂质含量增高以及易患白内障等疾病的重要原因之一,黑枸杞中的原花青素,具有强大的抗氧化作用,可以逆转这一过程。另据报道,黑枸杞中的原花青素,由于分子结构中有电子的羟基(酚基)部分,是由优良的氢或中子的给予体,有很强的抗氧化能力。在体内约为维生素E的50倍,为维生素C的20倍。据法国科学院的试验报告,认为原花青素是迄今为止所有发现最强、最有效的自由基清剂之一,尤其是在体内活性,是其他抗氧化剂不可比拟的。
6、降血糖:防治继发性糖尿病:黑枸杞提取物具有显著的降血糖和防治糖尿病的功能。研究表明,黑枸杞多糖对正常小鼠的血糖和糖耐量的影响以及对四氧嘧啶致高血糖小鼠的保护作用表明,分别给正常小鼠灌喂一定量的黑枸杞多糖,其结果使血糖明显降低。糖耐量实验表明,一定量的黑枸杞多糖可明显对抗正常小鼠给予一定量葡萄糖引起的血糖升高。研究明显,黑枸杞多糖对正常及糖尿病模型动物均有降血糖作用。另据研究,黑枸杞可有效控制餐后血糖,明显降低餐后血糖峰值,从而形成血糖峰值期胰岛素的需求量,减轻胰岛素细胞分泌胰岛素的负荷,从而达到保护胰岛素细胞的作用。长期服用还能降低空腹血糖的作用。实验表明,无论对正常人,还是对糖耐量降低者服用后都可以降低餐后血糖峰值和降低餐后血糖水平,防止继发性糖尿病。还有报道,动物实验结果表明,黑枸杞原花青素有助于降低糖尿病患者的血糖。能使动物胰腺细胞胰岛素产量增加50%。美国密歇根大学科研究人员表示,食用水果和其他含有原花青素成分会对人体和胰岛素水平产生重大的影响。
7、防治糖尿病视网膜病变:糖尿病视网膜病变是视网膜微血管病变,其表现为,糖尿病人血糖波动对会引起血压、血管等相应变化,造成眼底血管出血等连锁反应,影响到视网膜的功能。研究表明,黑枸杞中的花青素具有强大的抗氧化功效,有保护糖尿病大鼠视网膜氧化损伤的作用。临床研究显示,黑枸杞花青素可降低糖尿病视网膜患者血清中LPO含量,升高维生素C含量和SOD活性,具有显著的防治糖尿病视网膜病变的作用。据美国国立卫生研究院研究证实,黑枸杞中的原花青素对治疗糖尿病和高血压引起的眼部疾病有效,尤其有助于防治糖尿病和高血压等引起的眼部血管损害及造成视网膜损害。另外,黑枸杞花青素对与年龄相关的黄斑变性、白内障等眼部疾病有一定的作用。
(二)、沙棘提取物(Seahuckehorn),沙棘是生在青藏高原海拔3000米以上一种野生植物-沙棘果。由于青藏高原特殊的地理生态环境和气候条件,高寒缺氧,日照时间长,昼夜温差大,孕育疗具有特殊的生物活性物质含量丰富,是其他各地沙棘的上品,生活在青藏高原的藏民族视沙棘为“神仙果”,有极强的药用价值。在藏医巨著《四部医典》和《青藏药史》都有论述。沙棘为胡颓子科植物沙棘的果实。性温、味酸涩。具有祛痰止咳、消食化滞、活血散瘀的功效。用于消化不良、咳嗽多痰、瘀血闭经等。
现代医学研究认为,沙棘具有增强免疫力、恢复体力、消除疲劳、强精神、耐心肌缺血缺氧、降血压、降血脂、降血糖、防治动脉硬化、脑血栓、抗氧化、抗衰老、抗视力疲劳、抗癌有较好的预防和药理作用。
化学成分:沙棘含20多种氨基酸,不饱和脂肪酸、生物碱、黄酮、单糖类、多糖、白雀木醇、超氧化物歧化酶、甾醇类、三萜类、花青素、12种有机酸、维生素C、E、A、B1、B2、叶酸、胡萝卜素、钙、32种微量元素等200多种对人体有益的生物活性物质。被中外专家誉为“维生素的宝库”。
药理作用:1、提高免疫力:沙棘汁和沙棘油可增加免疫器官的重量,提高血清半数容血值抗体效价和再次抗原刺激抗体效价。促进巨噬细胞吞噬功能。沙棘黄酮的作用类似沙棘汁和沙棘油,并可使免疫功能低下的小鼠血抗体水平升高。
2、保护肝脏:沙棘籽油能减轻四氯化碳引起的小鼠肝损伤,对四氯化碳所致肝损伤小鼠丙二醛(MAD)和血清谷丙转氨酶(SGPT)的升高有明显的抑制作用,并能抑制扑热息痛所致肝脏的MDA增高,对抗受损肝脏谷胱甘肽(GSH)。另外,沙棘果汁可保护ccl4对乙酰氨基酚所致的肝损伤。
3、抗过敏:沙棘总黄酮腹腔注射能抑制小鼠的被动皮肤过敏反应,其抗过敏作用环节可能不在改善靶器官和细胞的反应,也不像扑尔敏药物等竞争靶细胞受体而发挥作用。可能与抑制抗原的结合或介质释放等因素有关。
4、抗氧化:研究显示,沙棘黄酮对活性氧具有明显清除能力。沙棘水煎剂给小鼠腹注或大鼠灌服可明显降低心肌等LPO提高SOD活性,还可阻断因体内物质过氧化产生的自由基,具有显著的抗氧化活性。据报道,沙棘中的胡萝卜素、维生素C、维生素E等成分对淋巴细胞中的过氧化氢(H2O2)所引起的DNA损伤有保护作用。小鼠淋巴细胞DNA链断裂后,在细胞培养中加入胡萝卜素、维生素C、维生素E,经培养后断裂链又重新连接。沙棘提取物作为高效的抗氧化剂,抑制氧化应激所引起的染色体畸变出现,提高受损DNA清除率,对染色体畸变DNA以及微核等遗传物质损伤的形成有抑制作用。
5、降血脂、防止动脉硬化:研究表明,沙棘提取物可显著降低血清和肝脏中的胆固醇及甘油三酯水平,尤以降低甘油三酯更为明显。能减少血管壁中胆固醇的沉积,防治高血脂症和动脉粥样硬化。动物实验显示,沙棘油和沙棘总黄酮能使血脂症大鼠血清中的总胆固醇,甘油三脂水平下降及肝组织中的总胆固醇含量下降,使血清中高密度脂蛋白含量升高,使血脂明显下降。
6、降血压:沙棘果中含有丰富的黄酮和维生素C,研究发现,在老年高血压病患者中,血液中的维生素C含量最高者,其血压最低。据证实,维生素C能提高血管弹性、扩张血管和保护动脉血管内皮细胞免受体内有害物质损害等作用。因此具有降血压作用。
7、降血糖和防治糖尿病并发症:国内外研究认为,植物黄酮有很好的降血糖作用。国内研究发现,沙棘中黄酮物质有助于克服体内“胰岛素抵抗因子”,从而使血糖过高的患者恢复正常血糖值。研究显示,广泛生长在青藏高原的天然野生沙棘,含有丰富的黄酮类物质,具有显著的抗“胰岛素抵抗因子”的作用。经实验证实,受试者的2型糖尿病食用后,血糖值恢复正常。沙棘黄酮是一种天然植物降血糖化合物,具有很好的降糖作用,它能阻止糖基化终产物的形成,因此,对防止慢性糖尿病并发症的发生和治疗有一定的作用。沙棘多糖对2型糖尿病也有良好的作用。据北京大学针对沙棘果汁对2型糖尿病动物降血糖作用进行了研究发现。沙棘果汁可以改善实验性糖尿病血糖和胰岛素水平。研究组以db/mm小鼠为对照,db/db小鼠为模型对照,二甲双胍(双胍类降糖药)干预的db/db小鼠为阳性对照,用沙棘果汁和富含不同剂量的白雀木醇的沙棘果汁进行干预。结果发现,沙棘果汁能显著降低2型糖尿病模型db/db小鼠的体重、减轻肥胖,且能显著改善2型糖尿病多食、多饮、多尿的症状;含有低剂量的白雀木醇的沙棘果汁对改善2型糖尿病多饮症状作用显著。沙棘果汁可能改善心脏、肾脏、脾脏、胰腺相关的并发症。实验还发现含低剂量的白雀木醇的沙棘果汁对空腹血糖改善作用最为明显,效果优于二甲双胍。含有低剂量的白雀木醇的沙棘果汁能显著促进2型糖尿病小鼠胰岛素的分泌,提高血清胰岛素水平;含有低、中剂量白雀木醇沙棘果汁比二甲双胍更能显著提高血清胰岛素水平,显著改善高血糖症状。研究人员证实,沙棘果实能改善2型糖尿病,白雀木醇是沙棘果汁中改善血糖、防治糖尿病的重要活性成分。,
此外,沙棘还具有延缓衰老、促进造血、保护胃黏膜、美容养颜、抗血栓、抗肿瘤等功效。
(三)、黄精提取物(Rhizoma Polygonati),青海黄精为百合科植物黄精的干燥根茎,性平、味甘。归脾、肺、肾经。具有补气养阴、补脾润肺、益肾的功效。用于脾胃虚弱、肾精亏损、精血不足、体倦乏力、口干食少、肺虚燥咳、内热消渴等,现代医学研究认为,黄精具有降血脂,抗动脉硬化、增强冠状动脉血流量、降血压、降血糖等作用。
化学成分:黄精含多糖类,甾体皂苷类、黄酮类、氨基酸、生物碱、甘露醇、蒽醌类化合物等。
药理作用:1、增强免疫功能:黄精提取物能提高机体免疫功能,促进DNA、RNA或蛋白质的合成。对免疫低下的病人的淋巴细胞转化具有促进作用。可使小鼠胸腺重量显著增加,能提高动物脾脏T细胞总数和外源胸腺依赖抗原的体液免疫水平,增强细胞免疫功能。小鼠灌服粗多糖可明显增加胸腺和脾脏质量,明显增强网状内皮系统对印度墨汁的吞噬能力。给免疫低下的小鼠灌服粗多糖,可明显增加脾脏重量。
2、保护肝脏:黄精多糖能明显降低CCl4中毒小鼠肝组织中丙二醛含量,具有保护肝脏的功能。
3、降血脂、抗动脉粥样硬化:黄精可使高血脂症大鼠的血清总胆固醇(CT)、血清甘油三酯(TG)降低。使实验性动脉粥样硬化程度减轻。给高脂血症兔灌服黄精煎剂,能明显降低三酰甘油β-脂蛋白胆固醇(TC),减轻主动脉壁斑块及冠状动脉硬化。
4、降血糖:黄精提取物对四氧嘧啶小鼠高血糖病理模型有明显的降血糖作用。黄精甲醇提取物对正常及链脲霉素诱发的血糖升高小鼠均有降血糖作用,并能明显对抗肾上腺素所引起的血糖升高。其降血糖作用与抑制肝糖酵解系统的功能有关。另据报道,黄精提取物具有降糖化血红蛋白的作用。黄精有补气养阴、润肺益肾的功效。所含的黄精多糖可抑制高血糖状态下的蛋白非酶糖基化过程,从而导致糖基化终产物生成减少,以降低糖化血红蛋白,还可预防糖尿病微血管病变。特别适宜糖尿病微血管并发症(糖尿病肾病、糖尿病视网膜病变)服用。
5、扩张冠脉、抗心肌缺血:黄精甲醇提取物能明显增强蟾蜍心脏及大鼠心房的收缩力,也可增加犬冠脉血流量。水浸液可增加离体兔心冠脉血流量。给兔静脉注射黄精溶液,有对抗神经垂体素所致急性心肌缺血的作用。
6、抗疲劳:黄精煎剂可显著延长小鼠游泳时间,提高小鼠活动能力。该作用与其降低肌酸酸酶有关。
另外,黄精还有抗氧化、延缓衰老、降血压、抗炎、抗病原体等功效。
(四)、山楂提取物(hawthorn),又名山里红果。为蔷薇科植物山楂或野山楂的果实,性微温,味酸、甘。归脾、胃、肝经。具有消食化积、活血散瘀。用于内食积滞、胃脘胀满、瘀血闭经、高血脂症等。现代药理研究认为,具有降血脂、降血压、减肥、降血糖、帮助消化、耐缺氧、保护胃黏膜、调节肠道菌群、通便、改善生长发育、抗氧化等作用。
化学成分:山楂含有机酸及黄酮类化合物、蛋白质、氨基酸、多种维生素和矿物质等。
药理作用:1、降血脂:山楂具有降低血中胆固醇及甘油三酯含量的作用,山楂中不同的成份对各种模型均有显著的降血脂作用。山楂提取物可使冠心病患者血桨中HC浓度逐渐降低,同时,血桨TC,TG浓度显著下降。山楂浸膏灌服可使动脉粥样硬化兔血胆固醇和器官上的脂质沉积降低。山楂颗粒给兔口服,能降低实验性高脂血症和血清胆固醇与β-脂蛋白,对家兔动脉硬化有治疗效果。另有实验表明,以山楂为主的纯中药制剂消瘀片可使实验性高脂血症兔血清总胆固醇和低密度脂蛋白-C明显下降,而对高脂血症大鼠血清总胆固醇、甘油三脂,低密度脂蛋白-C和APOB含量的降低作用更为明显,且同时可降低高脂膳食所致肝脂肪变性的程度及肝重量系数。山楂水煎剂给豚鼠灌胃,可增强肝细胞微粒体及小肠黏膜匀浆胆固醇生物合成限速的活性。据报道,国外用山楂治疗高血脂症和冠心病已有很多年。国内研究证实,山楂醇制剂、浸膏对实验动物动脉粥样硬化、高血压、高血脂有防治作用。
2、降血压:山楂中的黄酮水解物、三萜酸,分别以静脉、腹腔及十二指肠途经给药,可降低麻醉猫的血压。山楂总提取物或山楂总皂苷均可引起小鼠、兔及猫血压下降。实验还证明,山楂与槲寄生、臭梧桐合用,其降血压作用增强,作用时间延长。山楂降血压的作用机理因成分不同而异,主要是山楂总黄酮扩张外周血管为主。
3、减肥降脂:山楂能增强胃中消化酶分泌,促进消化,所含的脂肪酶可促进脂肪分解,山楂酸等多种有机酸可提高蛋白酶活性,可以促进脂肪类食物消化,有效消除体内多余脂肪的作用。另外山楂健脾、清胃、化积消积的功能有减肥、控制体重的作用。
4、强心:山楂提取物能增强蟾蜍离体以及收缩力,且持续时间较长。三萜类成分对自然疲劳和水合氯醛所致的衰弱蟾蜍心脏停跳有消除疲劳或恢复跳动的作用。
5、抗心律失常:山楂浸膏对家兔因脑垂体后叶素引起的心律不齐有一定的抑制作用。山楂黄酮及皂苷对家兔因乌头碱引起的心律失常也有促进其恢复作用。山楂中的三萜酸类能增加冠状血管流量,并能提高心肌对强心苷的作用敏感性,增加心排出量,减弱心肌应激性和传导性,具有抗心室颤动,心房颤动和阵发性心律失常。
6、扩张冠状动脉:山楂浸膏、山楂黄酮及皂苷都具有扩张冠脉血管的作用,能增加冠状动脉血流量,但不降低心肌耗氧量和氧利用率。
7、增加冠脉血流量:山楂降脂颗粒对兔、犬都有扩张冠脉血管,增加动脉血流量的作用。用放射性86铷测量证明,山楂黄酮水解产物均能增加小鼠心肌营养性血流量,其中水解产物作用最强,此作用可能与山楂扩张冠脉血管,改善冠脉循环有关。
8、抗心肌缺血:山楂提取物有预防或减轻异丙肾上腺素引起的豚鼠心肌缺血或坏死作用,对脑垂体后叶素引起的家兔或大鼠急性心肌缺血亦有明显的预防和对抗作用。
9、缓解血管痉挛:山楂浸膏和水解产物对氯化钾引起离体血管条痉挛有缓解作用,其缓解率与潘生丁相近。
10、抗血小板聚集:用三磷酸腺苷为诱导剂,观察山楂煎剂在体外对大鼠血小板聚集的抑制作用,结果表明,山楂煎剂在体外有一定的抑制血小板聚集作用。
11、保肝:生山楂可降低高脂饮料所致SD大鼠组织丙二醛、TC、TG的含量,清除肝脏内堆积的三酰甘油,减少脂肪酸对肝细胞毒性作用。使谷丙转氨酶、谷草转氨酶指标降低,达到降血脂、保肝的作用。黄酮类化合物对多种原因引起的肝损伤具有显著的保护作用。进一步研究,山楂提取液对自由基诱导透明质酸解聚有保护作用,并能明显抑制慢性乙醇中毒模型小鼠肝腺苷脱氢酶活性,表明山楂具有保护肝功能的作用。
12、增强免疫力:山楂对兔血清溶菌酶的含量、血管血凝抗体滴度、心血淋巴细胞E玫瑰花环形成率及淋巴细胞转化率均有显著的增高作用。显示山楂对体液免疫和细胞免疫均有促进作用。
13、抗疲劳和耐缺氧:山楂具有抗疲劳作用。能降低体内乳酸;降低血清尿素氮,促进糖原储备提高肝糖原含量,并可以显著延长机体耐缺氧时间,提高缺氧能力,能延长小鼠在缺氧下环境下的存活时间,山楂还具有显著的而缺氧作用。,因而具有抗疲劳和耐缺氧作用。
14、抗菌:山楂水煎剂对金黄色葡萄球菌、炭疽菌、痢疾杆菌、大肠杆菌具有较强的抑制作用。
(五)、决明子提取物(cassla seed),为豆科植物决明的成熟种子。性微寒,味甘、苦、咸。归肝、大肠经。具有益肾清肝、清热明目,润肠通便的功效。用于目赤涩痛、羞明多泪、头痛眩晕、目暗不明、润肠通便等疾病。现代医药研究表明,决明子降血脂、降血压、降血糖、保护肝脏、减肥、提高免疫力、通便、抗疲劳、抑制肠道菌群、改善视力、祛痤疮、祛除黄褐斑等作用。
化学成份:含蒽醌类、决明子苷A、B、C、决明子内酯、决明酮、氨基酸、维生素A、谷甾醇、棕榈酸、硬脂酸及亚油酸等。
药理作用:1、降血脂:动物实验表明,决明子能明显降低血清中的甘油三酯浓度、抑制胆固醇升高、肝内甘油三酯、动脉粥样硬化斑块形成作用。提高高密度脂蛋白的含量,增加高密度脂蛋白与低密度脂蛋白的比值,改善体内胆固醇的分布。其降脂作用与决明子所含的芦荟大黄素、大黄素等有关,这种物质有促进肠道管运动,抑制胆固醇的吸收作用。临床用决明子开水冲泡代茶饮用,治疗24例高脂血症患者,1个月后血清总胆固醇平均下降26%,1年后平均下降38.7%。
2、降血压:决明子水煎剂及醇浸液对麻醉动物具有降血压作用,可使动物收缩压和舒张压均明显降低。临床上对17例阴虚阳亢高血压患者,用决明子、夏枯草水煎服,可明显提高降血压疗效。
3、保护肝脏:决明子中含有的大黄酚具有保肝作用。而萘并吡喃酮糖甙对半乳糖胺所致的肝损害有明显的保护作用和对抗肝炎病毒的作用。
4、减肥降脂:研究表明:决明子有平脂降脂,久服益精气,轻身,具有良好的降脂减肥作用。现代药理研究证明,决明子能促进脂类物质代谢和抑制体内对脂类物质的吸收,减少脂肪在肝脏的沉积并促进排出体外,降低机体内脂质水平。另外,决明子还具有润肠通便作用,可干扰脂肪与碳水化合物的吸收,抑制脂合成作用。
5、抗血小板聚集:决明子中的葡萄糖钝叶素,葡萄糖橙钝叶决明素,葡萄糖甙能强烈的抑制由二磷酸腺苷、花生四烯酸、胶原引起的血小板聚集。
6、提高免疫力:决明子对细胞免疫有抑制作用,对体液免疫无影响,而对巨噬细胞吞噬动能有增强作用。
7、抑菌:决明子醇浸出物或煎剂对多种皮肤真菌及细菌有抑制作用。大黄素对金黄色葡萄球菌、大肠杆菌、绿脓菌、肺炎球菌、流感杆菌及副伤寒杆菌在体外有不同程度的抑制作用。
8、利尿:决明子含大黄酚、大黄素甲醚对15-羟基前列腺素脱氢酶有弱的抑制作用,因而可减缓具有利尿作用的前列腺素的代谢,使利尿时间延长。
9、通便:决明子水煎剂灌服小鼠,可使排便次数明显增加。
(六)、红曲(Monascus purpureus Went)又名红曲色素(莫那克林类、洛伐他汀)。红曲是以大米发酵产生的一种天然色素,在我国已经有几千年的应用历史,这种天然色素也是一种营养素,具有一定的营养和药理作用。近些年来,红曲在医药、食品等领域广泛使用。现代医学研究表明,红曲的生物活性作用,有降血脂、降血压、降血糖、抗衰老、免疫抑制、保护肝脏、抗肿瘤、促进骨骼生长、防治骨质疏松症等作用。
化学成分:红曲中的次生代物质含有莫那克林系列,γ-氨基丁酸、氨基葡萄糖、甾醇、皂甙等活?性成分。
药理作用:1、降血脂:研究认为,在人体内的胆固醇合成中,对胆固醇的合成限速酶(HMG-CoA还原酶),具有高效特异抑制作用,能有效阻断体内胆固醇的合成。人体中的70%的胆固醇由体内合成,因此,抑制内源性胆固醇过多的合成,能调节机体总胆固醇水平,从而降低血浆中胆固醇及低密度脂蛋白胆固醇和升高高密度脂蛋白胆固醇,抑制动脉粥样硬化斑块的形成;保护血管内皮细胞;抑制脂质在肝脏沉积,对重症胆固醇血症也很很好的作用。有研究表明,红曲中的成分莫那克林K是重要的调节血脂功能因子。莫那克林K的化学结构相同于洛伐他汀,因此,红曲具有降低胆固醇、甘油三酯,并可以调节胆固醇的结构,提高高密度脂蛋白胆固醇,降低低密度脂蛋白胆固醇。其作用机理是因为红曲不仅含有莫那克林K,还有其他功能成分。有临床研究,红曲可使血浆总胆固醇下降35%-45%,低密度脂蛋白胆固醇下降30-40%,甘油三酯有中等程度下降。对洛伐他汀的研究结果显示,用每晚40mg和每日两次40mg治疗6周,对家族型高血脂患者,总胆固醇下降24%和34%,低密度脂蛋白胆固醇下降27%和39%,甘油三脂下降27%和12%,高密度脂蛋白分别升高10%和8%。
2、降血压:红曲具有明显的降血压作用。对18周龄普通饲料中加入10%的红曲和10%的混合制剂进行试验结果显示,加10%的混合剂效果最好。有报道,红曲降血压表现为综合效果,除了红曲中含有的降血压因子γ-氨基丁酸外,还有其他降压成分和增效因子,是多种成分的共同作用的结果。
3、抗氧化:有研究红曲中含有的辅酶Q10是细胞代谢及细胞呼吸的激活剂,具有抗氧化作用,能抑制线粒体的过氧化,以保护生物膜结构的完整。
4、增强免疫力:研究表明,红曲具有非特异性免疫增强作用,能提高吞噬细胞的吞噬率,增加抗体的产生,改善T细胞功能。因此,红曲具有增强免疫功能的作用。
另外,红曲还有降血糖、抗肿瘤、延缓衰老、防治骨质疏松等功效。
(七)、白藜芦醇(Resveratpol Res),又称芪三酚,是含有芪类结构的非黄酮类多酚化合物,广泛存在于葡萄、松树、虎杖、桑椹及花生等的天然植物及果实中。近年来,国内外学者对白藜芦醇的生物学功能进行了深层的研究,表明白藜芦醇具有抗氧化、增强免疫力、降血脂、降血压、降血糖、减肥、护肝、抗炎、改善血液循环、防治心脑血管疾病、抗血栓、抗菌、抗突变、抗辐射、防癌抗癌、改善视力、延缓衰老、诱导细胞凋亡及雌激素调节等多方面有益人类健康的生物药理活性。
药理作用:1、抗氧化和清除自由基:白藜芦醇具有很强的抗氧化和清除自由基的功效。氧化和自由基的损伤是引起细胞DNA损伤进而使细胞恶变的重要机制之一。白藜芦醇不仅可以抑制低密度脂蛋白氧化,还能抑制膜脂的过氧化,减少过气化氢的产生,保护细胞免受过氧化作用的伤害和组织受损等。白藜芦醇的抗氧化作用,主要是通过清除或抑制自由基的生成,抑制脂质过氧化反应,调节过氧化相关的酶活性等机制发挥抗氧化作用。
2、降血脂:研究表明,白藜芦醇能显著降低高脂大鼠血清胆固醇水平,且呈剂量依赖关系,对连续给予6周高脂饲料引起的高脂血症家兔血脂水平也有显著对抗作用。可显著降低胆甾醇酯和甘油三酯的分泌,使VLDL和LFL产生量也明显下降。给患有脂肪肝及高脂血症的兔子喂食白藜芦醇后发现,甘油三酯和总胆固醇在肝脏中的积聚明显减少。实验显示,白藜芦醇具有良好的降血脂作用,可用于临床高血脂病人的治疗。
3、降血压:据报道,西班牙一项新研究首次发现,红酒中的白藜芦醇可降低血压,研究显示,心脏病高危男性每天饮用2杯无醇红酒,4周会血压明显降低。研究人员证实,红酒中的白藜芦醇物质具有降血压功效。其机理是白藜芦醇可增加机体内一氧化氮水平。人体内的一氧化氮分子有助于放松血管,同时降低收缩压和舒张压,增加心脏等主要器官的血流量,因此具有降血压作用。
4、防治糖尿病:白藜芦醇可减轻胰岛素抵抗,调节代谢紊乱。据国内报道,SIRTI(沉默信息调节因子)基因是迄今为止在哺乳动物细胞中发现与沉默调控基因SIR2同源性最高的系物,是一种二氢尿嘧啶脱氢酶(NAD)依赖去乙酰化酶,参与众多基因转移,能量代谢及细胞衰老调节过程。最新研究表明,白藜芦醇作为SIRT1激活剂,具有拟“卡路里”限量的作用,可通过活化SIRT1下游的信号传导通路对糖尿病、心血管疾病与衰老相关的疾病产生重要的保护作用。SIRT1不仅可增加线粒体含量,延长细胞存活期,还能调控胰岛β细胞的胰岛素分泌功能,具有减轻胰岛素抵抗的作用,其机制可能与沉默酪氨酸蛋白磷酸酯酶IB(PRPIB)的表达相关。此外,SIRT1能通过激活转录因子并调节转移因子与C/EBP的相互作用增加血清脂联素的表达。国外研究表明,白藜芦醇在小鼠模型试验中具有降糖作用,能够提高对胰岛素的敏感性,因此具有治疗糖尿病的作用。
5、改善血液循环:白藜芦醇可以防止血小板聚集,并能使动脉放松,保护血管内细胞内壁,还可提高了信号分子一氧化氮的生成,促进血管扩张,改善血液循环。
6、减肥:一项白藜芦醇干预随机对照交叉研究中,11名健康肥胖患者每日摄入白藜芦醇或安慰剂,干预30天,结果显示,与安慰组相比,白藜芦醇显著降低了睡眠状态的代谢率,提高细胞内脂质水平,降低了肝内脂肪含量、血糖水平、血液甘油三酯水平、丙氨酸、氨基转移酶和炎症标记物IL-6、TNF-五等的表达。另据研究证实,白藜芦醇可能是通过激活SIRTI(沉默信息调节因子I)和PGC-α(过氧化物酶体增殖物激活受体Y辅酶激活因子1α)的活性而对膳食诱导大鼠肥胖与胰岛素抵抗起防治作用,并且将Sirti确定为白藜芦醇调节能量代谢平衡控制体重所需要依赖的一个关键基因。据国外报道,红酒中的白藜芦醇可防止肥胖,能抑制脂肪细胞生长。红酒进入人体后,白藜芦醇可自动转化为白皮杉醇。经消化分解酒精和白皮杉醇进入血液“攻击”脂肪细胞堆积部位。研究人员在测试中发现,白皮杉醇“粘上”新生脂肪细胞的胰岛素受体,阻碍脂肪细胞的生长粘住其他细胞,由于白皮杉醇的存在新生脂肪细胞的生长遭阻碍或完成抑制。研究证实,白皮杉醇改变了脂肪生长,即新生脂肪细胞成长为成熟细胞过程中的基因表达,基因功能和胰岛素活动。脂肪生成是一个重要的分子目标。白皮杉醇正是“攻击”这一目标来阻碍或抑制脂肪堆积,防止身体长胖。另据美国报道,白藜芦醇燃烧脂肪的效果特别好,它能燃烧脂肪细胞的速度比正常速度快出2.4倍。
7、抗炎:血管炎症是2型糖尿病和心血管疾病的共同病理生理基础,以往的研究显示白藜芦醇具有抗炎作用。研究者发现,白藜芦醇具有血小板依赖性抗血栓形成和抗炎特性,对于具有心血管疾病的2型糖尿病患者,采用白藜芦醇治疗4周,部分炎症和代谢标志物水平显著改善,即果糖氨,高敏C反应蛋白和总胆固醇水平显著降低。英国研究发现,红洒中的白藜芦醇有助于对抗炎症。研究人员将实验鼠分为两组,先给一组注射白藜芦醇。再给两组小鼠同时注射强炎性药剂,结果显示,未注射白藜芦醇的小鼠表现出严重的败血症症状,而事先注射白藜芦醇的小鼠则安然无恙,研究发现,白藜芦醇抑制了引发炎症的两种主要蛋白质。
8、防治心血管疾病:白藜芦醇通过抗氧化、抗炎、抗血小板聚集、抗凋亡,调节血管生成及功能等多个信号途径,对改善心肌缺血,内皮的细胞损伤,动脉粥样硬化斑块形成,心肌肥大和心律失常等具有明显的效果。进一步研究,白藜芦醇可增加一氧化氮合成酶的表达,增加体内一氧化氮含量,松驰血管,发挥保护心血管的作用。利用以上两种作用及增大钙激活的钙通道活动和雌激素样作用,起到防治心血管病的作用。
9、保护肝脏:白藜芦醇具有很强的抗氧化活性,可有效调节肝细胞功能。研究发现,白藜芦醇对过氧化玉米油所致大鼠肝损伤有保护作用,可抑制大鼠肝中过氧化类脂质化合物的堆积,降低小鼠血清中的谷草转氨酶和谷丙转氨酶的水平以及脂质过氧化水平。另据研究,白藜芦醇可抑制小鼠肝脏甘油三酯和胆固醇的沉积。同时可通过抑制小鼠肝脏脂肪过氧化反应,促使天冬氨酸转氨酶和丙氨酸转氨酶水平上升,通过血清上升的两种酶对肝脏具有很好的保护作用。
10、抗血栓:白藜芦醇可抑制脂氧化酶合成,该酶存在于白细胞、心脏、大脑、肺和脾脏中。因此白藜芦醇可防止血管中血液凝块的形成,且在使用可乐宁高血压药物治疗后,白藜芦醇也可同样抑制血小板聚集及动脉粥样硬化斑块形成。
11、延缓衰老:据报道,意大利科学研究发现,葡萄中含有的白藜芦醇能使鱼延寿。服用白藜芦醇鱼的寿命可延长50%。有学者发现,白藜芦醇作为最强的SIRTI,参与有机生物平均生命周期的调控,且已证实摄入白藜芦醇能使酵母、线虫、果蝇和低等鱼类等的寿命延长。另据美国报道,红酒中的白藜芦醇能改善实验鼠健康状况和延长寿命的作用。随着年龄的增长,人体染色体的完整性受到破坏,而白藜芦醇可激活一种可恢复染色体健康的蛋白质,从而起到延缓衰老的作用。另有报道,白藜芦醇能延长人体酵母菌的寿命,具有延长人体寿命的作用。此外,白藜芦醇还具有防癌抗癌、抗菌、抗过敏、抗辐射、保护视力、保护神经,提高记忆力、抗突变、诱导细胞凋亡等功效。
(八)、姜黄素(Curcumin),姜黄素是从姜科、天南星科的一些天然植物的根茎中提取的一种化学成分;是植物界很稀少的具有二酮的色素,为二酮化合物,具有许多生物学活性功效。医学研究表明,姜黄素具有降血脂,抗肿瘤,抗氧化,抑制炎症反应、利胆、抗类风湿作用。
生理功能:1、抗癌活性:据报道,研究发现,姜黄素及其衍生物可抑制由1,2一二甲基肼(DMH)诱发的小鼠结肠癌变前异常腺体增生,腹腔注射(IP)DMH,三周后,口服(PO)四氢姜黄素15-12周,结果发现,癌变前异常腺体增生质量/小鼠质量为(46.6±17.7)%,而对照组(不给四氢姜黄素)即此项比值为(63.3±19.4)%,这说明姜黄素及其衍生物四氢姜黄素可阻止小鼠结肠癌变前异常腺体的增生。以上研究结果看出,姜黄素的抗癌效应是通过保护正常细胞对抗各种致癌因素或抑制肿瘤细胞发展的某些环节而起作用。另据美国报道,姜黄素能有效抑制皮肤癌细胞生长。研究人员使用不同剂量和不同次数姜黄素对三批黑素瘤进行了实验,结果表明,姜黄素能使黑素瘤皮肤癌细胞更容易自我毁灭。研究人员还发现,姜黄素有助于防止乳腺癌肿瘤扩散到肺部,还可抑制了两种可使肿瘤细胞永不死亡的蛋白质。另据日本报道,姜黄素具有抑制细胞增生的作用。研究人员将姜黄素放到两种据认为癌症细胞增生有关的酶中,在37℃的温度下使它们发生反应,结果证实,姜黄素比现在使用的抗癌药物能更好地抑制酶的活性。姜黄素的抗癌活性其作用是抗氧化功效表现。因为癌症最主要是由人体内产生大量氧自由基引发的,而姜黄素作为一类多酚,具有一定的吸附自由基作用,于是通过清除人体产生的自由基,显示出具有一定的抗癌作用。
2、抗氧化:姜黄素具有很强的抗氧化作用,可清除体内有害自由基,对OH·自由基的清除率可达69%。姜黄素能提高大鼠肝组织均浆中多种抗氧化酶的活性,能使SOD、过氧化氢酶,谷胱苷肽过氧化酶的活性分别提高约20%,在比较了各种姜黄素和α-生育粉的抗氧化能力最强。经试验,姜黄素对大鼠胸、心、肝、肾、脏等组织都有明显的抗氧化作用,使过氧化脂质(LPO)含量降低,从而延缓组织老化。
3、抗炎抗菌:炎中是诱发多种慢性疾病诱因。有人通过研究发现姜黄素具有较强的抗炎作用,而且其作用非常类似于非甾体抗炎药抗炎作用。随后,作为有效的非甾体消炎药进入II期临床试验,对18名风湿性关节炎和骨关节炎病人做短期、双盲、交叉试验,显示出令人满意的结果,又有研究,通过灌胃的方式给予甲醛诱发关节炎的大鼠姜黄素和姜黄素钠,结果其抑制率为45-50%。还有研究表明,姜黄素抑制大鼠腹腔巨嗜细胞分泌的容酶体和花生四烯酸的代谢,腹腔注射(IP)姜黄素1h,可明显抑制花生四烯酸的代谢,减少前列腺素E2(PGE2)的释放达45%,白介素B4为61%,白介素C4为34%,同时对胶原酶,弹性蛋白酶和透明质酸酶的分泌抑制率分别为57%、61%和66%,表明姜黄黄对抑制炎症反应的发展过程起到抗炎作用。
4、降血脂:姜黄素可显著降低血清和肝脏胆固醇及甘油三酯水平,尤以甘油三酯作用更为明显。研究实验认为,姜黄素可能是通过抑制胆固醇的合成,起到降低高血脂的作用。姜黄素具有显著的降低血清和肝脏中的胆固醇及甘油三酯,可用于肥胖和IV型高血脂的治疗。实验显示,姜黄素能显著降低血清总胆固醇和甘油三酯的作用,尤以降低甘油三酯最为明显,起到治疗高血脂症的作用,其作用尤于降脂宁和烟酸。研究证实,姜黄素降血脂作用机制是通过抑制体内胆固醇的合成,来降低血清和肝脏中的甘油三酯来实现的。并对肝脏也有保护作用。
5、抗病毒:姜黄素具有抗病毒的生理活性。在对姜黄素研究中发现其对人类免疫缺陷病毒(HIV)有抑制作用,主要通过抑制HIV长末端重复序列(LTR)活性,抑制病毒复制的相关酶(逆转录酶、蛋白酶和HIVI整合酶)及对细胞因子的影响,进一步抑制HIVI整合酶的蛋白复制。有研究指出,Tat是被HIVI感染细胞所分泌的一种物质,而Tat反过来又可激活HIVI-LTR,姜黄素可抑制Tat与HIVI-LTR之间的这种相互作用,抑制率达70-80%。
6、保护肝脏:姜黄素有对抗四氯化碳和半乳糖胺对大鼠原代谢细胞培养时所致的损伤,对四氯化碳碳和半乳糖胺引起的大鼠原代肝细胞的毒性也有对抗作用。姜黄素还能使升高的谷草、谷丙转氨酶值分别降低,预先给予姜黄素可减轻大鼠对乙酰胺基酚所致肝损伤。国外报道,最新研究发现,咖喱中的姜黄素对肝脏有保护作用。研究人员将患有慢性肝炎的大鼠对照实验显示,喂食咖喱的老鼠数周后肝炎症状减轻。对照组无明显变化。因此,姜黄素具有明显的保肝作用。进一步的研究,姜黄素还有保护肝细胞的作用,对治疗肝病有一定的功效。
7、防治糖尿病、降血糖:据国外研究,姜黄素可防治糖尿病,能使糖尿病高危患者免于患病。研究者发现,每天服用一定量的姜黄素时间9个月,可以阻止前期糖尿病发展为糖尿病,前期糖尿病是指在患有高血糖症和低血糖症的患者中存在葡萄糖代谢障碍,虽然未达到2型糖尿病的诊断标准,但可能完全发展为糖尿病。先前的实验发现,姜黄素可以帮助细胞抵抗炎症、抗氧化、而炎症和氧化可以导致一系列的疾病。研究人员对240名患有前期糖尿病的成年人被随机实验服用姜黄素胶囊和安慰剂,9个月后,116名服用安慰剂的病人中有19人发展为2型糖尿病,而服用姜黄素的119人中没有1个发展为2型糖尿病。研究人员发现,姜黄素能够增强胰岛素β细胞的功能,正是这种细胞释放出调节血糖的胰岛素。研究人员说,是姜黄素的抗炎症作用保护了胰腺β细胞免受损害。
8、改善脂质代谢:姜黄素能降低β-α脂蛋白的浓度。研究认为,姜黄素可通过抑制胆固醇的合成,起到治疗高血脂的作用。肥胖患者大多伴有高血脂症,长期高血脂会导致动脉粥样硬化,引起早衰或心脏病。对肥胖症的治疗除节食外,减少体脂是主要目的。实验显示,姜黄素具有降低胆固醇和甘油三酯的作用,尤以降低甘油三酯最为明显,使体重接近正常。其机理可能是姜黄素降低血脂或肝脏内甘油三酯的作用显著。可用于肥胖症和IV型高血脂的治疗,并且能预防脂肪肝。
(九)、苹果多酚(Apple Polyphenols AP),苹果多酚是苹果中所含的一种多元酚类物质的通称,也广泛存在水果和蔬菜中,具有多种生物功能。祖国医学认为,苹果味甘凉,具有生津清肺、健脾、益胃、养心等功效,现代研究认为,苹果多酚具有抗氧化,降血脂、抗动脉粥样硬化、减肥、防治心血管病,抗过敏、防突变、消臭、防紫外线、养颜美容、消除黄斑、防癌抗癌等作用。
化学成分:原花青素,黄酮醇类(槲皮苷配糖体)酚酸类和二羟查尔酮类(根皮苷糖体)等。
生理功能:1、抗氧化:苹果多酚的抗氧化特性是通多种途径综合作用实现的,苹果多酚具有很强的供氢和电子能力,对多种活性氧有清除作用,可将单线态氧还原成活性较低的三线态氧,从而减少氧自由基的产生的可能性,同时也可有效清除各种自由基。其次,苹果多酚可以使邻位二酚羟基与金属离子螯合,减少金属离子对氧化反应的摧化;另外,对于有氧化酶存在的体系,苹果多酚能与其发生沉淀,抑制氧化酶的活性,对自由基也有间接清除作用。
2、降血脂:研究表明,苹果多酚可使血清中的总胆固醇和甘油三酯明显下降。动物实验显示,在大鼠饲料中加入适量的苹果多酚以比较其对脂质代谢的影响,结果显示,大鼠血清中的胆固醇浓度明显下降,血清中的甘油三酯的量则有较大幅度的下降,高密度脂蛋白升高。其作用机制是苹果多酚通过抑制肠道对外源性胆固醇的吸收,加速胆固醇的代谢及促进排泄,抑制胰脂肪酶的活性,而降低对外源性甘油三酯的吸收。另有报道,目前已有研究显示,苹果多酚能有效调控机体胆固醇代谢,抑制内源性胆固醇合成。根皮苷属于黄酮中的二氢查尔酮苷类,是苹果多酚含有的特征活性物质。研究结果显示,根皮苷能够降低HMG-COA还原酶mRNA及蛋白质的表达水平,从而减少胆固醇在机体内的合成,能有效调控血液中LDL-C向肝脏逆转运。研究显示根皮苷能有效上调LDL-R的mRNA表达水平,从而加速血液中LDL-C向肝脏进一步代谢转化。因此,根皮苷调控胆固醇代谢的机制是通过减少胆固醇内源合成,加速血液低密度脂蛋白胆固醇向肝脏转运以胆固醇向胆汁酸转化,增强胆固醇排泄等代谢途径来实现的。
3、降血压,研究认为,人体肾脏的功能之一是分泌血压增高的“血管紧张素”和是血压降低的“舒缓激肽”以保持血压的平衡。当促进两类物质转换的酶活性过强时,血管紧张素转换酶增加血压就上升,苹果多酚可抑制血管紧张素转换酶活性的作用,因而苹果变酚可起到降低血压的作用,另有报道,苹果多酚还能改善血管的渗透性,能有效增加心肌和血管壁弹性,有效降低血压。
4、降脂减肥:苹果多酚可抑制脂肪在小肠中的吸收并促进排泄,还可抑制脂肪在肝脏内的合成,促进脂肪燃烧,以达到减肥瘦身的目的。据国外报道,日本研究人员发现,苹果多酚可以抑制脂肪的吸收,从而减少脂肪在体内蓄积的作用。研究者对4周龄的大鼠进行实验结果表明,饮料中添加苹果多酚组大鼠的内脏重量的增加在一定程度上受到抑制,同时发现,大鼠粪便量也有增加的倾向,其血清中的中性脂肪和胆固醇值的上升受到了抑制;在肝脏中促进脂肪燃烧的一种酶(COA氧化酶)的活性被激活,大鼠体内脂肪合成相关酶系中的脂肪酸合成酶的活性也有所降低,因此具有降脂减肥的作用。据美国报道,苹果多酚具有燃烧脂肪的作用,有助于减少体内的白色脂肪,降低患肥胖症的风险。
5、降血糖:糖尿病是由于胰岛素分泌不足和血糖过高而引起糖脂肪和蛋白质代谢紊乱。苹果多酚对人体的糖代谢障碍具有调节作用,能降低血糖水平,从而有效预防和治疗糖尿病。另据报道,苹果多酚可抑制人体对葡萄糖的吸收能力。其作用机理主要是通过阻止葡萄糖的吸收和降低碳水化合物的两种方式来降低血糖含量。另外,苹果多酚能增强α-淀粉酶等酶类的活性可使单糖的产生下降,从而降低血糖浓度。
6、抗炎:据报道,研究表明,在切除卵巢大鼠膳食中添加0.25%的根皮苷在机体内具有较好的抗炎效果。
另外,苹果多酚还可抗过敏、抗衰老、抗突变、防治冠心病、防癌抗癌、防晒、美容养颜、祛除黄褐斑等作用。
(十)、α-亚麻酸(a-Linolenic acid ALA),是DHA和EPA的母体,主要存在于亚麻籽油,紫苏籽油之中,在人体内可转化为DHA、DPA、EPA、抗凝酶等活性物质,α-亚麻酸属于ω-3系列多烯脂肪酸,为不饱和脂防酸,是构成人体组织细胞的主要成分之一,在人体内不能合成、代谢,为必需脂肪酸必需从体外摄取。现代药理研究认为,α-亚麻酸能增强智力和免疫力、保护视力、降血脂、降血压、降血糖、抑制出血性脑疾病和血栓性疾病,抑制癌症的发生与转移,预防心肌梗塞和过敏性疾病,炎症以及减缓人体衰老等。另外,α-亚麻酸还可预防和治疗糖尿病、类风湿病、抑郁症、精神分裂症、老年痴呆症、过敏、哮喘、肾病和慢性阻塞性肺炎等。
生理功能:1、降血脂,抗动脉硬化:α-亚麻酸能显著降低血清中甘油三酯的含量,防止动脉硬化的作用,还可抑制内源性胆固醇的合成。动物实验表明,α-亚麻酸通过抑制肝脏内的甘油三酯和低密度脂蛋白的生成,提高高密度脂蛋白胆固醇的含量,改善低密度脂蛋白与高密度脂的比例。α-亚麻酸可清除血液中的甘油三酯,减少内源性胆固醇的合成,增加体内胆固醇与胆酸的排泄,还可做为前列腺的前体物质前列环素,具有很强的抗凝和血管扩张作用,预防动脉硬化。据国外报道,澳大利亚科研人员发现,补充ω-3脂肪酸可治疗高甘油三酯血症,结果表明,在ω-3脂肪酸试验组,患者甘油三酯水平在饮食干预后降低6%,在完成治疗后降低了56%。随机效应模型显示,ω-3脂肪酸降低甘油三脂的效果明显好于对照组(P=0.0487)。
2、防治心血管疾病:α-亚麻酸具有降低胆固醇、甘油三脂和低密度脂蛋白的作用。其代谢产物具有抗凝血和扩张血管,增加血管弹性,抑制血小板聚集,具有防治心血管病的作用。据国外报道,美国研究人员对近8万名女性长达16年的跟踪研究证实,经常食用α-亚麻酸的女性与基本不食用的女性相比,其心脏功能衰竭和冠状动脉疾病所导致的死亡风险可减少46%,心脏病衰竭的猝死风险降低为68%。
3、抗血栓:实验证实,α-亚麻酸可抑制血小板能和血清素的游离基,从而抑制血栓疾病的发生。α-亚麻酸等不饱和脂肪酸具有降低血小板AA水平和抑制血栓素A生成的作用,还可使血小板活性减弱,有效控制血小板在血管壁凝集,从而减少血栓形成。
4、减肥:α-亚麻酸能促进能量产生,使人体获得更多的氧气,有助于增加氧气比率、代谢率、能量水平及体力。有助于减轻体重,α-亚麻酸在人体会增加代谢率及能量消耗,燃烧更多的卡路里,能对脂肪细胞产生一定的作用,使其转化为像荷尔蒙同样的前列腺素,这种物质能让人保持苗条。另外,α-亚麻酸有助于人体排出存在于肾脏内多余水分,而这些水分是某些人体超重的重要因素。
5、防治糖尿病,研究表明,α-亚麻酸可明显修复胰岛的功能,促进胰岛中β细胞分泌胰岛素,提高受体对胰岛素的敏感性。连续服用3周,血糖平衡下降,服用6-10个月,胰岛功能可得到恢复。
6、抗炎:α-亚麻酸对各种炎症和细胞因子有抑制作用,能减少炎症因子的生成。另有报道,α-亚麻酸具有良好的抗炎作用,有实验发现,风湿性关节炎患者摄入α-亚麻酸后可以完全停止服用非类固醇抗炎药物。另有部分可将非固醇抗炎药物减半。
7、降血压:α-亚麻酸能合成PGE1,PGE1能降低动脉血压,减少外周血管阻力,但对正常血压不会降低。
8、增强免疫功能:α-亚麻酸有助于强化免疫系统,在人体免疫系统中必需脂肪酸,能保护基因免受损害,对增强人体免疫力,提高人体抵抗力具有重要的作用。有研究发现,α-亚麻酸可影响细胞膜结构的完整性、稳定性和流动性,影响细胞运动,受体形成,受腰带与配体的结合等,从而减少细胞因子的产生和释放,改善肺、肝脏、肠的血供和氧代谢。因此,α-亚麻酸在细胞水平诱导的改变较为持久,是有效的免疫调节营养素。
9、延缓衰老:据报道,美国研究人员发现,ω-3脂肪酸能延缓人体衰老的进程。成年人服用ω-3脂肪酸有助于改善体脂肪比例,在一定程度上对“端粒”(染色体、端粒位上的丝点,其主要功能是保持基因的稳定状态)有益,人体中的脂肪比例越低端粒就越长,对健康越有益。研究还发现,ω-3脂肪酸能将血液中的自由基对人体造成的损害降低15%,另外,ω-3脂肪酸还能降低人体内白细胞介素6的含量和人体内炎症水平。
(十一)、大豆皂甙(Soybean saponin),大豆皂甙是从大豆中提取的一类具有较强生物活性的化学物质,其分子由低聚糖与齐墩果稀三萜连接而成,即由萜类同系物(称为皂甙元)与糖缩合形成的一类化合物,根据化学结构大豆皂甙可分为A、B、E三个系列。近年来国内外大量的研究表明,大豆皂甙具有抗氧化、抗病毒、抗炎、抗溃疡、抗癌、增强机体免疫力等功能。能够防止过氧化脂质生成,降血脂、降低血浆中胆固醇含量、护肝、减肥、降血压、降血糖、抑制血栓形成,防治心血管疾病、延缓衰老等功效。
生理功能:1、降血脂:大豆皂甙能增加胆汁酸的分泌,可降低血中胆固醇和甘油三脂含量。有人用大豆皂甙与高脂饲料同时喂养家兔四周,结果家兔血清中胆固醇及甘油三酯明显低与单纯喂饲高脂饲料的家兔组。但大豆皂甙与基础饲料同时喂养家兔与单纯喂饲基础饲料的家兔相比,两者血清中胆固醇和甘油三酯含量并无明显差别,说明大豆皂甙对高脂肪膳食所致的高血脂症具有防治作用。美国研究发现,大豆皂甙可提高高密度脂蛋白,降低低密度脂蛋白,具有降血脂、防治动脉硬化作用。
2、降血压:研究表明,大豆皂甙能修复受损血管内皮细胞,使其重新恢复正常血压,从根本上稳定血压。大豆皂甙还能降低血液黏稠度,减少心肌耗氧量,改善心功能,增加微循环和末梢血管血流量,使血液流动学改变、护心、护脑、护肾、长期服用能有效对抗冠心病、脑心栓等高血压并发症。
3、降血糖:肌注大豆皂甙能明显降低糖尿病大鼠血糖、血小板聚集率及TXA2、PGI2值,提高胰岛素水平,有效抵抗糖尿病。
4、减肥,肥胖是由脂肪增多,尤其是中性脂肪过多会引起肥胖,而肥胖会导致动脉硬化、高血压及心血管等疾病。科学研究发现,大豆皂甙的重要功能抑制脂肪的吸收和在肝脏中形成,促进其分解代谢等。预防血栓,使血中胆固醇以及中性脂肪酸降低,改善高血压,动脉硬化以及高血脂等症,同时还能抑制葡萄糖转化为脂质的功能,长时间服用可以改变肠黏膜及表面组织,有效防治肥胖。
5、护肝:大豆皂甙能抑制脂肪和胆固醇在肝脏内积蓄,并促进快速分解与代谢,因而,减轻肝脏脂质代谢负荷,起到护肝的作用。另外,大豆皂甙还能抑制血中转氨酶的作用,对预防和治疗某些肝病也有效。
6、抗血栓:大豆皂甙具有抑制血小板聚集和凝血酶引起的血栓纤维蛋白形成,促进体内纤维蛋白的溶解。表明大豆皂甙能调整机体溶血系统,冠状动脉与脑血管血流量以及提高心肌供氧量等一系列功能。因此,大豆皂甙可抗血栓、脑溢血、冠状动脉硬化等心血管系统疾病。进一步研究发现,在离体条件下不同种类的大豆皂甙及总皂甙都可抑制纤维蛋白源向纤维蛋白转化,而大豆皂甙1.II还能激活纤维蛋白溶酶活性。
7.增强免疫力,据国内报道,动物实验证明,大豆皂甙可提高LAK(淋巴因子激活的杀伤性细胞)细胞、NK(自然杀伤性细胞)细胞的活性,增加IL-2(白介素)的分泌及增强T、B淋巴细胞对CONA(刀豆蛋白A)、LPS(脂多糖)的增殖能力,表明大豆皂甙在体内对小鼠的免疫功能有广泛的作用。大豆皂甙对T细胞功能有增强作用,特别是T细胞功能的增强使IL-2的分泌增强,而IL-2的功能使T细胞存活并增殖,促进T细胞产生淋巴因子,增强诱导杀伤性T细胞,NK细胞的分化及提高LAK细胞活性,从而具有增强免疫功能。此外,大豆皂甙还能使荷瘤鼠的脾脏,胸腺明显增加。
8、抗氧化、抑制过氧化脂质生成:研究发现,大豆皂甙可抑制血清中脂质的氧化,进而抑制过氧化脂质的生成。进一步证实,大豆皂甙可使机体自身调节,增加体内超氧化物歧化酶的含量,以清除自由基,进而减轻自由基的损害程度,减少脂质过氧化的发生中使机内过氧化脂质含量下降,从而起到抗氧化作用。
9、抗病毒:有人研究大豆皂甙对人类艾滋病毒及感染和细胞的生物学活性均有一定的抑制作用,认为大豆皂甙在艾滋病的预防和治疗中都非常有效。还有研究发现,大豆皂甙对单纯疱疹病毒1型(HSV-1)、腺病毒H型等DNA病毒及脊髓灰质炎病毒、柯萨奇等RNA病毒均有明显的抑制作用,表现出广谱抗病毒能力。大豆皂甙抗病毒的机制,多数人认为是大豆皂甙对病毒的直接杀伤作用。另外,大豆皂甙能增强机体局部吞噬细胞和NK细胞的功能,从而可增强机体细胞抵抗病毒的免疫力。
另外,大豆皂甙还具有抗衰老、抗突变、抗癌等功效。
(十二)、海藻酸钠(satium alginate SA)又名褐藻胶。是从褐藻植物中提取的一种天然高分子多糖,也是一种水溶性膳食纤维,具有多种生理学独特功能。有降血压、降血糖、调节血脂,增加饱腹感、减肥、增强免疫力、抗辐射、整肠、保护胃肠道、防癌抗癌,排出重金属等功能。
生理功能:海藻酸钠
1、降血脂:海藻酸钠具有降低血清总胆固醇和甘油三酯,升高高密度脂蛋白,降低低密度脂蛋白,从而防治动脉硬化。动物实验表明,海藻酸钠中高剂量组的总胆固醇及总甘油三酯含量与高脂对照组比较,前者降低了10.6%、15%,后者降低了19.8%和27.1%,低、中、高实验组的高密度脂蛋白胆固醇与高脂对照组比较,分别升高17.5%、33.7%、51%。有报道对31位高血脂症成人患者进行口服海藻酸钠,30天后检测,结果显示,血清总胆固醇、甘油三酯和低密度脂蛋白明显下降。这是因为海藻酸钠能抑制胆固醇在小肠内吸收并促进排出,从而使胆固醇和甘油三酯下降。
2、降血压:现代医学研究认为,血压升高与人体内氯离子含量升高有关,而海藻酸钠能与氯离子结合,并将其排出体外,使体内氯离子水平降低,使血管紧张素II形成减少,体内缓激肽增加,血管扩张起到降压作用。
3、降血糖:胰岛素的活性与人体内的PH值有关,若PH值上升0.1,则胰岛素的活性上升约30%。海藻酸钠不仅能效调节人体内酸碱平衡,提高海藻酸钠的活性和胰岛素的敏感性,从而起到降血糖的作用。
4、强化肝脏功能:长期饮酒,可引起酒精性脂肪肝和肝硬化。肝脏是人体最重要的代谢器管,同时肝脏还能分解、代谢人体内的酒精等有毒物质。研究发现,海藻酸钠能增强肝脏的功能,促进人体毒素分解并促进排泄,防止脂肪肝和病毒性肝炎发生。
5、降脂减肥:海藻酸钠具有独特的降脂减肥作用,其减肥重要作用是抑制食欲。海藻酸钠属于可溶性膳食纤维的特性,具有很强的吸水性,使人产生饱腹感,从而减少食物的摄入量,来减少动物脂肪和胆固醇的吸收,达到减肥的作用。据国外报道,海藻酸钠化合物能阻止身体对脂肪的吸收,对减肥具有一定的功效。英国纽卡斯尔大学研究发现,海藻酸钠能有效抑制人体对脂肪的消化与吸收。当海藻酸钠含量上升4倍之后,人体对抗脂肪吸收的能力提高75%。
6、吸附重金属,海藻酸钠其分子中存在有羟基、氨基等化学基团,因而对许多重金属离子具有很好的螯合作用。不仅能有效吸附或捕集重金属离子,而且还能抑制铅等重金属在肠道内的吸收,并促进排出体外。
7、增强免疫力:海藻酸钠能明显增强小鼠腹腔巨噬细胞的吞噬功能,并有增强体液免疫功能的作用。研究表明,海藻酸钠能明显提高小鼠红细胞C36受体花环抑制率和红细胞C36受体花环促进率,降低红细胞免疫复合物花环率和血清中红细胞C36受体花环抑制率,结果证实,海藻酸钠对小鼠的红细胞免疫功能有明显的促进作用。
8、抗辐射:海藻酸钠对辐射具有明显的防护作用,它能使接受急性辐射的小鼠存活率提高63%,还能显著减轻小鼠骨髓细胞辐射遗传的损伤,能促进造血干细胞等增殖和分化,激活细胞内多条信号传递系统,提高对辐射的耐受力,促进造血系统受辐射损伤后的恢复。
9、抗菌:海藻酸钠在试管内同心性毛癣菌、铁锈色小芽胞癣菌,腹股沟表皮癣菌,红色表皮癣菌等皮肤真菌有明显的抑制作用。对枯草杆菌也有一定的抑制作用。
10、抗肿瘤:海藻酸钠能抑制小鼠S180肉瘤的生长。对小鼠巨噬细胞有较强的免疫调节作用,这是抑制肿瘤的机制之一。此外,海藻酸钠还具有降血压、降血脂、降血糖、抗病毒等功能,治疗心血管病及肠道系统疾病。
综上所述,本产品具有滋补肝肾、活血化瘀等功效。用于降血脂、降血压、降血糖、减肥、抗炎、通便、保护肝脏、抗动脉粥样硬化、抗血栓、防治心脑血管疾病等功效。
六、制作工艺:
1、调配混合:先将设计配方中原料按物理特性进行混合。
2、搅拌:将混合后的原料送入搅拌机,充分搅拌均匀。
3、压片:将搅拌均匀的原料送入压片机,压制成片剂。
4、检验包装:将压制成的片剂,检验合格包装成为正式产品。
调配混合工序是将设计配方中的原料按物理特性进行混合的过程。搅拌工序是将混合的原料搅拌均匀的过程。压片工序是将搅拌均匀的原料送入压片机压制成片剂的过程。检验包装工序是将压制成的片剂,检验合格,包装成为正式产品。
七、质量标准:
1、理化指标:
黑枸杞提取物 | g/100g | 12.30 |
沙棘提取物 | g/100g | 7.50 |
黄精提取物 | g/100g | 12.30 |
山楂提取物 | g/100g | 7.50 |
决明子提取物 | g/100g | 7.50 |
红曲 | g/100g | 24.00 |
白藜芦醇 | g/100g | 5.00 |
姜黄素 | g/100g | 2.50 |
苹果多酚 | g/100g | 15.00 |
酚α-亚麻酸 | g/100g | 15.00 |
大豆皂甙 | g/100g | 5.00 |
海藻酸钠 | g/100g | 12.30 |
2、服用方法:每日服用3次,每次1-1.5克
3、适用人群:适应用高血脂、高血压、高血糖、肥胖、心脑血管疾病等人群。
八、具体实施方式:
实施例:取黑枸杞提取物50千克、沙棘提取物30千克、黄精提取物50千克、山楂提取物30千克、决明子提取物30千克、红曲100千克、白藜芦醇20千克、姜黄素10千克、苹果多酚60千克、α-亚麻酸60千克、大豆皂甙20千克、海藻酸钠50千克为原料混合,充分搅拌均匀,送入压片机压制成片剂,检验合格包装成为正式产品。
Claims (1)
1.降血脂黑枸杞片制作工艺,其特征为:黑枸杞提取物50千克、沙棘提取物30千克、黄精提取物50千克、山楂提取物30千克、决明子提取物30千克、红曲100千克、白藜芦醇20千克、姜黄素10千克、苹果多酚60千克、α-亚麻酸60千克、大豆皂甙20千克、海藻酸钠50千克为原料,经过将以上原料按物理特性混合,充分搅拌均匀,送入压片机,压制成片剂,检验合格,包装成为正式产品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410415853.1A CN104206955A (zh) | 2014-08-17 | 2014-08-17 | 降血脂黑枸杞片 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410415853.1A CN104206955A (zh) | 2014-08-17 | 2014-08-17 | 降血脂黑枸杞片 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104206955A true CN104206955A (zh) | 2014-12-17 |
Family
ID=52089168
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410415853.1A Pending CN104206955A (zh) | 2014-08-17 | 2014-08-17 | 降血脂黑枸杞片 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104206955A (zh) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104757535A (zh) * | 2015-03-09 | 2015-07-08 | 苟春虎 | 黑枸杞减肥片(茶) |
CN105663444A (zh) * | 2016-04-11 | 2016-06-15 | 吉林大学 | 一种复方免疫增强及抗衰老剂及其制备方法 |
CN106174580A (zh) * | 2016-08-29 | 2016-12-07 | 苟春虎 | 黑枸杞降血糖防并发症片 |
CN106924438A (zh) * | 2017-04-21 | 2017-07-07 | 中国科学院西北高原生物研究所湖州高原生物资源产业化创新中心 | 一种具有缓解视疲劳的黑果枸杞糖浆及其制备工艺 |
CN107441264A (zh) * | 2017-08-23 | 2017-12-08 | 洛阳士雄聚元医疗集团股份有限公司 | 一种治疗高脂血症的中药 |
CN108208267A (zh) * | 2018-01-26 | 2018-06-29 | 刘化君 | 一种降血压、降血脂、降血糖和减肥塑形作用的袋泡酵素养生茶 |
CN112007020A (zh) * | 2020-09-02 | 2020-12-01 | 毛蕴衡 | 含牡丹甾醇和α亚麻酸的组合物及其应用 |
CN113730547A (zh) * | 2021-09-17 | 2021-12-03 | 江苏协合转化医学研究院有限公司 | 一种降脂、溶解血栓组合物及其制备方法和应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1593551A (zh) * | 2004-06-25 | 2005-03-16 | 浙江省医学科学院 | 降血脂胶囊或片剂及其制备方法 |
CN1961744A (zh) * | 2006-12-08 | 2007-05-16 | 富天桂 | 一种保健食品 |
CN101692895A (zh) * | 2009-10-19 | 2010-04-14 | 闫聿逊 | 一种降脂保健食品 |
CN102160664A (zh) * | 2011-02-21 | 2011-08-24 | 苟春虎 | 儿童营养饮料 |
CN103431377A (zh) * | 2013-07-17 | 2013-12-11 | 苟春虎 | 降血糖防并发症 |
-
2014
- 2014-08-17 CN CN201410415853.1A patent/CN104206955A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1593551A (zh) * | 2004-06-25 | 2005-03-16 | 浙江省医学科学院 | 降血脂胶囊或片剂及其制备方法 |
CN1961744A (zh) * | 2006-12-08 | 2007-05-16 | 富天桂 | 一种保健食品 |
CN101692895A (zh) * | 2009-10-19 | 2010-04-14 | 闫聿逊 | 一种降脂保健食品 |
CN102160664A (zh) * | 2011-02-21 | 2011-08-24 | 苟春虎 | 儿童营养饮料 |
CN103431377A (zh) * | 2013-07-17 | 2013-12-11 | 苟春虎 | 降血糖防并发症 |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104757535A (zh) * | 2015-03-09 | 2015-07-08 | 苟春虎 | 黑枸杞减肥片(茶) |
CN105663444A (zh) * | 2016-04-11 | 2016-06-15 | 吉林大学 | 一种复方免疫增强及抗衰老剂及其制备方法 |
CN105663444B (zh) * | 2016-04-11 | 2020-05-22 | 吉林大学 | 一种复方免疫增强及抗衰老剂及其制备方法 |
CN106174580A (zh) * | 2016-08-29 | 2016-12-07 | 苟春虎 | 黑枸杞降血糖防并发症片 |
CN106924438A (zh) * | 2017-04-21 | 2017-07-07 | 中国科学院西北高原生物研究所湖州高原生物资源产业化创新中心 | 一种具有缓解视疲劳的黑果枸杞糖浆及其制备工艺 |
CN107441264A (zh) * | 2017-08-23 | 2017-12-08 | 洛阳士雄聚元医疗集团股份有限公司 | 一种治疗高脂血症的中药 |
CN108208267A (zh) * | 2018-01-26 | 2018-06-29 | 刘化君 | 一种降血压、降血脂、降血糖和减肥塑形作用的袋泡酵素养生茶 |
CN112007020A (zh) * | 2020-09-02 | 2020-12-01 | 毛蕴衡 | 含牡丹甾醇和α亚麻酸的组合物及其应用 |
CN113730547A (zh) * | 2021-09-17 | 2021-12-03 | 江苏协合转化医学研究院有限公司 | 一种降脂、溶解血栓组合物及其制备方法和应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104206955A (zh) | 降血脂黑枸杞片 | |
CN103431377A (zh) | 降血糖防并发症 | |
CN109123643A (zh) | 一种谷物代餐球的制备方法 | |
CN102511869B (zh) | 红枣生姜浓浆 | |
CN102919330B (zh) | 一种松花粉纤维饼干 | |
CN110612111A (zh) | 含有丹参提取物的预防、改善或治疗内脏脂肪型肥胖的组合物 | |
CN101766274B (zh) | 含竹叶黄酮的抗氧化功能食品组合物 | |
CN108404019A (zh) | 复方菊苣根调节嘌呤代谢紊乱的固体制品及其制备方法 | |
CN104644901A (zh) | 心脑血管疾病缓解期长期防治的中药制剂及其制备方法 | |
CN104757535A (zh) | 黑枸杞减肥片(茶) | |
CN103168815A (zh) | 一种银杏苦荞饼干及其制作方法 | |
CN102526339B (zh) | 一种调节血脂、增强免疫力的保健药物的配方 | |
KR20140017932A (ko) | 탱자 발효물에 의한 비만개선효과물질의 조성 | |
KR101217080B1 (ko) | 생약 추출물을 유효성분으로 포함하는 숙취 해소용 조성물 및 그의 제조 방법 | |
CN112791175A (zh) | 提高人体新陈代谢机能和排出代谢废物的中西药组合物及其制备方法 | |
CN102940650B (zh) | 用于解酒的蜂胶乙醇提取物、制备方法及在生产肠溶片中的应用 | |
CN111387345A (zh) | 一种复合多糖组合物及其制备方法 | |
KR101491493B1 (ko) | 감귤 과피 및 구아바 추출물을 포함하는 항염증 약학 조성물 | |
CN106174286A (zh) | 高级金枸杞营养果酱 | |
CN101284100B (zh) | 虫草复方延春养颜胶囊 | |
CN104855960A (zh) | 创伤感染手术及其它应急状态非全营养配方食品 | |
CN105031248B (zh) | 一种含有硒虫草的可辅助降血糖的保健品 | |
CN109364202B (zh) | 一种组合物及其制备方法和应用 | |
CN109549206A (zh) | 一种溶栓及预防心血管疾病的功能性食品及其制备方法 | |
CN103611051B (zh) | 防治冠心病中药制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20141217 |
|
RJ01 | Rejection of invention patent application after publication |